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ABSTRACT
Diverse health challenges such as rising incidence of metabolic disease, rapid aging, and increasing antibiotic resistance are facing current humanity. Most diseases
involve many genes in complex interactions, as well as environmental influences that
are often not well understood. High-throughput advances in genome sequencing, transcript measurement, and protein measurement have been developed to address these
challenges. A number of disease biomarkers have been identified as a result of an
increased understanding of cellular functions. The observation of such systems-level
cellular behavior has naturally extended to the metabolite level, leading to the study
of metabolomics.
Measurement of the metabolites in a biological sample represents a snapshot of
the physiology of the cell. The study of metabolites can help assign biochemical
functions to so-called orphan genes (genes that cannot be ascribed a function by
sequence analogy) and validate them as molecular targets for therapeutic intervention.
Integration of metabolomics data with other omics data will provide a more complete
picture of the functioning of organisms.
Due to the chemical diversity of metabolites, the identification process in metabolomics
is currently less advanced than that in proteomics and transcriptomics. Development
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of a computational workflow to improve and accelerate metabolite identification and
biochemical pathway reconstruction is required for metabolomics to increase its impact in systems biology. The goal of this thesis is to design, develop, and validate
methods for metabolite structure identification as well as defining their biochemical
functions by predicting their metabolic pathway associations.
First, I propose BioSM; a cheminformatics tool that uses known endogenous mammalian biochemical compounds and graph matching methods to identify endogenous
mammalian biochemical structures in chemical structure space. The results of a
comprehensive set of empirical experiments suggest that BioSM identifies endogenous mammalian biochemical structures with high accuracy (95%). In addition,
results suggest that approximately 13% of PubChem compounds are mammalian
biochemicals. Thus, BioSM may be useful for searching large chemical databases in
metabolomics applications where the number of potential false positives is very large.
BioSM is freely available at http://metabolomics.pharm.uconn.edu.
A major downside of BioSM, granting its encouraging results, was its need to
exhaustively search all known biochemical structures to be able to make a decision
about the molecular structure under investigation, which resulted in an undesirably
high run time. To tackle this concern, I introduce BioSMXpress, designed and developed as an enhancement to BioSM. BioSMXpress is, on average, 8 times faster than
BioSM without compromising the quality of the predictions made. BioSMXpress
will be an extremely useful tool in the timely identification of unknown biochemical
structures in metabolomics.
Finally, I present TrackSM; a bioinformatics tool designed to predict the metabolic
pathway classes as well as the individual pathways to which small molecules might
be associated with, based only on their molecular structures. Validation experiments
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show that TrackSM is capable of associating 93% of the structures to their correct
pathway classes as defined by KEGG and 88% of them to the correct individual
KEGG pathway. These impressive results suggest that TrackSM may be a valuable
tool to aid in recognizing the biochemical functions of small molecules.
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Chapter 1
Introduction

1.1

Motivation

Detailed knowledge of the molecular nature of biological systems has become readily
available thanks to the current developments in genome sequencing as well as related
high-throughput technologies [11, 12]. Systems biology is a discipline that strives to
explain biologic phenomena through the net interactions of all cellular and biochemical components within a cell or organism [13]. This has led to the establishment
of the so-called omics technologies, referring to a group of high-throughput research
tools, including genomics, transcriptomics, proteomics, metabolomics, peptidomics,
glycomics, lipidomics, and interatomic. Figure 1.1.1 displays a schematic of omics
technologies. These technologies are based on comprehensive analyses of genetic information, including information from DNA, RNA, proteins and small compounds
(metabolites) from tissue samples, cell lines, and body fluids [14]. Investigators are
responsible for obtaining, integrating, and analyzing complex data from multiple ex5
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perimental sources using interdisciplinary tools [15].

Figure 1.1.1: Schema of omics technologies, their corresponding analysis targets, and
assessment methods. Adapted from [1]
In the post-genomic era, researchers became interested in studying the metabolome
to describe the relationship between the genome and the phenotype in cells and organisms [16]. This was influenced by the fact that an organisms phenotype is not
revealed by the complete understanding of the state of its genes, messages, and proteins [17]. The metabolome is the complete set of metabolites in a cell or organism
[6]. Metabolites are small molecules, usually <1000 Daltons (Da), which are chemically transformed during metabolism. Metabolites are required for the maintenance,
growth and normal function of a cell. It is estimated that a metabolome may comprise anywhere from 1000 to 200,000 distinct metabolites depending on the organism
[10].

7
The rapid, high throughput analysis and characterization of metabolites within a
cell, tissue or biofluid of an organism in response to some external stress is referred
to as metabolomics [18]. The study of the metabolome is a reflection of enzymatic
pathways and networks encoded within the genome [19]. The interactions of the developmental processes and the changing environment over the lifetime of an organism
can be conveyed by the entire composition of metabolites. Metabolomics promises to
provide a more precise snap shot of the actual physiological state of an organism by
monitoring the overall effect of various factors acting on a cell [20]. The Future of
Metabolomics promises a comprehensive insight into the effective use of metabolomics
in drug discovery, drug repurposing, pre-clinical development and clinical trials [4].

1.2

Thesis Objective

The objective of this thesis is to develop computational methods and software tools to
aid in the diagnosis and treatment of human diseases. Particularly, tools to improve
and accelerate the identification of endogenous mammalian biochemical structures
and the prediction of their biological function by identifying the metabolic pathways
to which they might interfere with. These tools are designed to reach such decisions
based on chemical structural similarity methods. Work in this thesis was designed
with the following objectives:
1. Design and develop methods for metabolite structure identification. These
methods may be useful for searching large chemical databases in metabolomics
applications where the number of potential false positives is very large.
2. Design and develop bioinformatics tools for identifying the biochemical function
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of small molecules. This can be achieved by predicting the metabolic pathway
class or the individual pathways to which the compound might be associated
with.
3. Apply the above methods to unseen data for evaluation.
Successful implementation of the above objectives will result in a practical toolbox
that can be integrated with existing work flows for efficient metabolomics data analysis.

1.3

Thesis Structure

Chapter 2 gives background, related work, and approaches for different metabolomics
analyses approaches. This will be followed by an overview of some applications in
metabolomics and common metabolic platforms and strategies. Finally a review of a
general metabolic workflow. Chapter 3 describes different validation frameworks and
accuracy measures applied in this thesis. Chapter 4 describes the design, development
and validation of a cheminformatics tool, called BioSM that identifies endogenous
mammalian biochemical structures in chemical structure space. Chapter 5 describes
the design, development and validation of BioSMXpress, an enhancement to BioSM.
The speed up algorithm is described along with validation that the quality of the
predictions has not been compromised. Chapter 6 describes a bioinformatics tool,
referred to as TrackSM, designed to predict the metabolic pathway classes as well as
the individual pathways to which small molecules might be associated with, based
only on their molecular structures. Method validation is also discussed. Finally,
Chapter 7 offers conclusions and recommendations for future work.

Chapter 2
Background and Related Work

2.1

Introduction

Metabolomics is the critical level of post-genomic analysis. It can reveal changes
in metabolite fluxes that are controlled by minor changes within gene expression
measured using transcriptomics and/or by analysing the proteome that exposes posttranslational control over enzyme activity [21]. The term metabolomics was initially
defined, by the Nicholson Group at The Imperial College of London in 1999, as the
global analysis of all metabolites present in a sample [22]. While the term metabonomics was defined, by the Fiehn group at The Max-Planck Institute of Molecular
Plant Physiology in Germany in 2002, as the analysis of metabolic responses to drugs
and diseases [7]. Nowadays, both terms are generally considered to be synonymous
[2]. However, the monitoring of metabolite components (colors, smells and tastes) of
a patient’s body fluids, such as urine or saliva, to various medical conditions can be
traced back to ancient cultures [2, 20, 23, 24]. The field of metabolomics has seen
9
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explosive growth in the post-genomic era. The number of publications indexed by it
has grown exponentially to ˜2,123 PubMed indexed citations in 2013. Figure 2.1.1
displays a comparison of the number publications per year since the term was coined
in 1999 till 2013.

Figure 2.1.1: Comparison of the number publications/year for the keywords
”metabolomics OR metabonomics” in Scopus form 1999 to 2013.

2.2

Applications of Metabolomics

Metabolomics research has been applied to a variety of applications some of which are
microbiology [20, 25, 26, 27, 28, 29], plants [21, 30, 31, 32, 33] and medical science.
In regards to medical science, there are three broad areas that might benefit from
metabolomics (Figure 2.2.1). Metabolic profiling of individuals could be used
in personalized health care to work out patients susceptibilities to disease or their
responses to medicines, and to tailor their lifestyles and drug therapies accordingly
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[34, 35, 36, 37]. Metabolic profiling of populations could allow the identification of many metabolites as possible biomarkers for diseases or new insights can be
gained in the development or progression of disease [2, 4, 12, 24, 38]. Examples include non-invasive diagnosis of coronary heart disease [6, 7, 39], lung disease [15],
mental disorders [40], and cancer [1, 14, 41, 42, 43]. This is accomplished by comparing the metabolomes of healthy and diseased subjects. Finally, by identifying
biochemical pathways for disease, metabolomics could uncover new targets for drug
discovery [44], prioritize lead compounds, and assess toxicity non-invasive manner,
enabling the development of novel, smarter and safer drugs [2, 13, 43, 45, 46, 47] as
well as drug repositioning [48, 49, 50, 51, 52, 53]. It’s anticipated that within the
next 10 years metabolomics will become a standard tool in the pharma industry as
validated metabolomic-based biomarkers begin to emerge and cost-effective screens
are established [47].

Figure 2.2.1: Applications of metabolomics. Adapted from [2]
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2.3

Metabolomics Approaches and Platforms

The metabolomics experiment provides unique challenges to fulfill the goal of improving the current status of biological information related to the metabolome and
more generally functional genomics [5, 8, 9]. A typical metabolomics research flow
starts with the design of an experiment plan then proceeds to sampling and sample
preparation followed by data acquisition using analytical instrumentation, and finally data processing and data interpretation using a variety of statistical techniques
[32, 54]. Figure 2.3.1 shows the typical scheme employed in metabolome analysis.
For a metabolomics study to be successful, all steps, starting from the definition of
the biological question and the experimental design up to the biostatistics, should
be optimized and appropriate for their intended use [24]. The ultimate goal of a
metabolomics experiment is to identify and quantify all of the metabolites in a cell or
tissue in a given state at a given point in time [9]. However, it is currently impossible
to do so simultaneously in a single, high throughput platform due to the fact that
no single extraction technique or analytical instrument can isolate and detect every
metabolite within a biological sample [30, 55]. These difficulties are further amplified
by issues such as human error in sample preparation and extraction, sample storage
and instrument reproducibility [5]. Additionally, metabolomics is challenging due to
the fundamental diversity in chemical structure, size, abundance and reactivity of the
collection of metabolites in any biological samples [21, 55].

2.3.1

Analytical Technologies

Metabolomic platforms can be categorized based on the detection method. Detection
methods include nuclear magnetic resonance (NMR) [56], Fourier transformation in-
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Figure 2.3.1: Schematic representation of a metabolomics experimental workflow. Based on the study design, biological samples are collected, processed
and subsequently analyzed using various analytical platforms. Adapted from
http://www.cial.uam-csic.es/metabolomics/workflow.html
frared spectroscopy (FT-IR) [28, 57], and mass spectrometry (MS) [58] coupled to
separation techniques such as high performance liquid chromatography (HPLC) [59],
gas chromatography (GC) [24], or capillary electrophoresis (CE) [6]. The use of different analytical platforms provides complimentary information that can be integrated
for deeper metabolome coverage [60]. Generally, the technology platform of choice
depends on the type of sample to be analyzed [9]. Sample types commonly investigated include plant tissue, plasma, urine, cerebral spinal fluid, mammalian tissue,
and cultured eukaryotic and prokaryotic cells [61].
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2.3.2

Metabolomics Approaches

Analytical approaches for metabolomics can be categorized broadly into two distinct
groups: targeted or untargeted [62]. This is dependent upon whether the methodology implemented is designed to quantify a number of specific metabolites (targeted)
or to measure a generally larger set of metabolites restricted only by the sensitivity
and applicability of the analytical platform(s) and data processing employed (untargeted). These approaches can further be subdivided as metabolic profiling, using an
untargeted approach or metabolite identification and quantitation using a targeted
approach [55], as seen in Figure 2.3.2. Different jargon for the definition of metabolic
approaches have been used by various metabolomic research areas some of which can
be found in Table 2.3.1.
Targeted metabolomics is commonly driven by a specific biochemical question
or hypothesis that motivates the investigation of one or more related pathways of interest [45, 55]. These studies involve the use of biochemical and analytical tools for the
quantification of known metabolites of biological interest [62]. Targeted metabolomics
studies can be effective for pharmacokinetic studies of drug metabolism as well as for
measuring the influence of therapeutics or genetic modifications on a specific enzyme
[45].
Untargeted metabolomics is global in scope, usually hypothesis-free, and has
the aim of simultaneously measuring as many metabolites as possible from biological
samples [63]. It is used for the identification of metabolic pathways that are altered
following distresses of biological systems [3]. Since, untargeted metabolomics does
not require prior knowledge, it can be used to identify novel metabolic biomarkers of
disease and drug efficacy as well analyzing the global metabolic profile of the whole
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system [55]. Both targeted and untargeted metabolomics reveal the expected behavior of known metabolites, but only untargeted metabolomics allows the detection of
concurrent effects between variables which cannot be observed at an individual level.

Figure 2.3.2: Workflow illustrating both untargeted and targeted metabolomics approaches. Adapted from [3].

2.4

Untargeted Metabolomics

In contrast to targeted metabolomic results, untargeted metabolomic data sets are
exceedingly complex, with file sizes on the order of gigabytes per sample for some
new high-resolution mass spectrometry instruments. Manual inspection of the thou-
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Metabolomics

Unbiased identification and quantification of all the metabolites
present in a biological system.
Metabolome
Complete set of low-molecular-weight metabolites present in a
biological sample (i.e., biofluid, organism, bacterial community)
Metabolite
Qualitative and quantitative analysis of one or a few metabolites
target analysis related to a specific metabolic reaction.
Metabolite
Metabolic profiling Identification and quantification of a seprofiling
lected number of pre-defined metabolites, generally related to a
specific metabolic pathway(s).
Metabolic
Analysis of the metabolites secreted/excreted by an organism;
footprint
it may include environmental and growth substances. Does not
rely on the measurement of intracellular metabolites but rather,
on monitoring those that are secreted or fail to be taken up by
a cell or tissue [31, 32].
Metabolic
Unbiased, high-throughput, rapid, global analysis of samples
fingerprinting to provide sample classification. Analysis is oriented towards
defining clinically relevant differences rather than identifying
all the molecules present in a sample [30].
Metabonomics Evaluation of tissues and biological fluids for changes in endogenous metabolite levels that result from disease or therapeutic
treatments
Metabolite
Also known as fluxomics. Labeled metabolites are fed into a
flux analysis
biosystem and the destination of the label is assessed, usually
in a time-dependent manner.
Table 2.3.1: Definitions and terms used in metabolomics. Adapted from [5, 6, 7].
Original references [8, 9]

sands of peaks detected is impractical. With recent developments in bioinformatic
tools, identification of metabolite peaks that are differentially altered between sample
groups has become a relatively automated process [4]. Several metabolomic software
programs that provide a method for peak picking, nonlinear retention time alignment,
visualization, relative quantification and statistical analysis are available [64, 65, 66].
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2.4.1

Metabolite identification.

One of the known bottlenecks in metabolomics is in the identification process of
unknown metabolites since currently available metabolomics software does not output
metabolite identifications. Rather, it provides a table of features with pvalues and
fold changes related to their difference in relative intensity between samples [4].
To determine the identity of a feature of interest, the accurate mass of the compound is first searched in an online chemical structure database. Databases range from
general chemical structure databases such as PubChem [67], ZINC [68] ChemSpider
[69] to specialized databases such as HMDB [70], DrugBank [71], or HumanCyc [72].
A list of freely accessible small molecule databases useful in metabolomics research
is presented in Table 2.4.1. A database match represents only a putative metabolite
assignment that must be confirmed by comparing the retention time and MS/MS
data of a model compound to that from the feature of interest in the research sample
(Figure 2.4.1) [4].

Figure 2.4.1: Untargeted metabolomics workflow. Adapted from [4]
A typical mass search in PubChem may yield several thousand chemical structures, whereas the same search in HMDB often results in less than a dozen. Both
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Database
PubChem
ChemSpider
Zinc

Metlin
HMDB
KEGG compound

DrugBank
PlantCyc
HumanCyc

Type
General
chemical
structure
database
General
chemical
structure
database
General
chemical
structure
database (commercially available
small molecules)
Metabolites and MS/MS data
Human metabolome database
A collection of small molecules,
biopolymers and other compounds relevant to biological systems
Drugs (approved, illicit, withdrawn and experimental)
Plant metabolites and pathways
Human metabolites and pathways

# of cpds
˜33 million

Reference
[67]

˜28 million

[69]

˜20 million

[68]

˜64 000
8,608
16,834

[64]
[65]
[73]

6,711

[71]

3,334
1,321

[74]
[72]

Table 2.4.1: Freely accessible small molecule databases. Adapted from [10].

types of databases have advantages and disadvantages. Querying a focused small
database such as HMDB makes identification relatively trivial if the unknown metabolite happens to be among the candidates. However, this approach cannot be used to
identify previously unknown metabolites. On the other hand, searching a large chemical database such as PubChem greatly improves the odds of finding the unknown
compound in the database. On the downside, the excessive number of potential
candidates in PubChem may lead to a large number of false positives making the
identification of the correct ”unknown” extremely difficult. However, by applying
carefully configured curation steps, the candidate list from a large database may
be shortened substantially. Initial curation steps may include removing disconnected
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structures, eliminating charged species, clustering stereoisomers and eliminating compounds containing elements other than C, H, N, O, P and S. These curation steps
alone can eliminate anywhere from 40% to 90% of candidates from the initial bin of
structures matching the molecular mass of the unknown [10].

2.4.2

Identifying Altered Metabolic Pathways

Metabolic pathways are characterized as a series of chemical reactions catalyzed by
enzymes connected in a way such that the reactants of one reaction are the products
of the previous one. Understanding these pathways is essential to understanding the
machinery of life [75]. The reconstruction of the metabolic network of an organism
based on its genome sequence is a key challenge in systems biology[76].
Metabolic pathways are a series of chemical reactions occurring within a cell.
In each pathway, a principal chemical is modified by a series of chemical reactions.
Chemical reactions are catalyzed by enzymes, and often require dietary minerals,
vitamins, and other cofactors in order to function properly. In addition, numerous
distinct pathways co-exist within a cell. This collection of pathways is called the
metabolic network. Pathways are important to the maintenance of homeostasis within
an organism. Figure 2.4.2 gives a glimpse of the complexity of a metabolic pathway.
By performing global metabolite profiling, also known as untargeted metabolomics,
new discoveries linking cellular pathways to biological mechanism are being revealed
and are shaping our understanding of cell biology, physiology and medicine [4].
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Figure 2.4.2:
The citric acid cycle is central to the chemical processing of carbohydrates, fats, and proteins to produce energy.
Adapted from
http://math.uwaterloo.ca/

Chapter 3
Basic Evaluation Techniques

3.1

Cross Validation Framework

Cross Validation (CV) is a statistical method used for estimating how accurately a
predictive algorithm will perform in practice while avoiding overfitting as well as to
tune learning model parameters [77]. This is accomplished by dividing data into two
segments: one used to train a model and the other used to validate the model. In
typical cross-validation, the training and validation sets must cross-over in successive
rounds such that each data point has a chance of being validated against. CV is also
used to compare the performance of two or more different algorithms and find out the
best algorithm for the available data, or alternatively to compare the performance of
two or more variants of a parameterized model.
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3.1.1

K-folds Cross Validation Framework

The data set is divided into k subsets. Each time, one of the k subsets is used as
the test set and the other k-1 subsets are put together to form a training set (Figure
3.1.1). Then the average error across all k trials is computed. The advantage of this
method is that it matters less how the data gets divided. Every data point gets to be
in a test set exactly once, and gets to be in a training set k-1 times. The variance of
the resulting estimate is reduced as k is increased. The disadvantage of this method
is that the training algorithm has to be rerun from scratch k times, which means it
takes k times as much computation to make an evaluation. A variant of this method
is to randomly divide the data into a test and training set k different times. The
advantage of doing this is that you can independently choose how large each test set
is and how many trials you average over.

Figure 3.1.1: K-folds cross validation. In this illustration k = 4

3.1.2

Nested Cross Validation Framework

Classification accuracy is empirically assessed using 2 -fold CV, with parameter tuning
performed by executing k -fold CV on the training data (Figure 3.1.2). Briefly, the
dataset is divided randomly into 2 halves; one half for model training and the other
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half for model testing. The training half is further randomly split into k roughly
equal parts, and then each part was used to evaluate classification accuracy of models
trained on the remaining (k −1) parts. The average accuracy measure of all k training
sets is used as the cutoff score when evaluating the testing data.

Figure 3.1.2: Nested cross validation framework

3.1.3

Leave-one-out Cross Validation Framework

Leave-one-out cross validation (LOOCV) is k -fold cross validation with k equal to N,
the number of data points in the set. That means that N separate times, the function
approximator is trained on all the data except for one point and a prediction is made
for that point (Figure 3.1.3).

Figure 3.1.3: Leave-one-out cross validation
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3.2

Analysis of Variance

The general purpose of the analysis of variance (ANOVA) is to test for significant
differences between means [77]. ANOVA is preferred when there is more than two
levels of an independent variable to compare. ANOVA can also analyze data from
several independent variables simultaneously. In this thesis, all the ANOVA analysis
was carried out using the Single Factor ANOVA function in Microsoft Excel 2007.

3.3

Accuracy Measures

Statistical measures used to evaluate the performance of classification models in this
thesis are defined in this section. The definition of some abbreviations used below
can be found in Table 3.3.1.
TP
FP
TN
FN

True positive
False positive
True negative
False negative

Correctly identified
Incorrectly identified
Correctly rejected
Incorrectly rejected

Table 3.3.1: Definitions of abbreviations used to explain accuracy measures

Sensitivity (SENS) refers to the proportion of actual positives which are correctly
identified, and is computed as

SEN S =

TP
TP + FN

(3.3.1)

Specificity (SPEC) refers to the proportion of negatives which are correctly identified,
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and is given by
SP EC =

TN
TN + FP

(3.3.2)

The Positive Predictive Value (PPV) is the proportion of positive test results that
are true positives, and is defined by

PPV =

TP
TP + FP

(3.3.3)

The Matthews Correlation Coefficient (MCC) [78], defined by

M CC = p

T P.T N − F P.F N
(T N + F N ) . (T N + F P ) . (T P + F N ) .(T P + F P )

(3.3.4)

is commonly used as a combined measure of the overall quality of two-class classifiers.
MCC can range from 1 to -1 where



1



M CC =
0




 −1

perf ect prediction
randomized prediction
perf ectly inverse prediction

Finally, the F-Score is the harmonic mean of SENS and PPV, i.e.,

F =2

SEN S.P P V
SEN S + P P V

(3.3.5)

Chapter 4
Identifying endogenous mammalian
biochemical structures in chemical
structure space

4.1

Introduction

The interpretation of the massive amount of data produced by high-throughput techniques is a major challenge in metabolomics [79]. The most common approach involves
matching experimentally determined features, such as a mass spectrum or retention
index, with computationally simulated features for a set of candidate compounds
downloaded from a general chemical structure database [66] Various on-line chemical structure databases (Table 2.4.1) provide the fundamental support for molecular
identification. The relative advantages or disadvantages of utilizing chemical structure databases vary depending on the size of the database. Small databases often
will not contain the candidate compound of interest. On the other hand, searching
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large databases such as PubChem, often results in a large number of false positives,
making identification of the ”unknown” extremely difficult. Hence, cheminformatics
methods are needed to more efficiently search large chemical databases in order to
identify unknown endogenous biochemical compounds. Ideally, these methods would
allow discrimination between candidate structures that are synthetic and candidate
structures that are biochemical [16, 80].
Nobeli et al. [81], using two-dimensional (2D) molecular structures and cheminformatics tools, reported the first attempt to solve this problem. They visually examined the 2D molecular structures of 745 E. coli metabolites and manually derived a
library of 57 structural fragments commonly found in those metabolites to reveal the
main constituents of metabolites and to assist in the classification of the metabolome
into biochemically relevant classes. Preliminary efforts correlating similarities between metabolites and protein structures, as well as with metabolic pathways were
reported. In related work, Gupta and Aires-de-Sousa [82] defined chemical space of
endogenous biochemicals using the KEGG/LIGAND database. Any compound in
KEGG that was involved in a metabolic reaction was included in the study. These
included metabolites from different species as well as xenobiotics. The chemical space
of non-metabolites was represented by a random set of commercially available compounds from the ZINC [83] chemical database. They compared both chemical spaces
based on 2D and 3D structures and descriptors of global properties. They found that
overlap between metabolites and non-metabolites was smallest in the space defined
by the global descriptors and suggested that the most discriminative features were
the number of OH groups, the presence of aromatic systems, and molecular weight.
Using a random forest (RF) [84] classifier and global molecular descriptors they were
able to correctly annotate 95% of the 1,811 KEGG compounds used for training the
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model. A RF is a collection of unpruned classification trees created by using bootstrap samples of the training data and random subsets of variables to define the best
split at each node.
Extending Gupta and Aires-de-Sousas work, Peironcely et al. [85] used 6,954
molecular structures in HMDB [70] to represent chemical space occupied by endogenous human metabolites and an updated collection of compounds from ZINC
as non-biological structures. Both datasets were clustered independently and 532
molecules (cluster centers) from each dataset, selected to represent each cluster, were
used for building the classification model. The remaining (6,422) molecules were used
for training the model. They showed that using MDL public keys [86] and RF resulted in the best accuracy for their classifier. The authors reported that 96% of
457 HMDB compounds not used for training the model, 54% of 6,532 DrugBank
[71] compounds and 22% of 6,312 compounds from ChEMBL [87] were classified as
endogenous metabolites.
Both Gupta & Aires-de-Sousa and Peironcely et al. employed fingerprints for
classification. Molecular fingerprints represent the structure of a molecule as a list
of binary values (0 or 1) that indicate the presence or absence of structural features
in the molecule [88]. A structural feature may include properties (such as molecular weight), the presence/absence of an element, an unusual or important electronic
configuration (such as triple-bonded nitrogen), rings and ring systems and functional
groups. An alternative approach is based on viewing a molecule as a graph and using
graph-matching algorithms to find common substructures. Previous work [81] suggests that matching common substructures may describe structural similarity more
accurately than fingerprint-based methods. Although this has been suggested, it has
not been explored due to concerns related to computational efficiency. In addition,
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this approach of matching common substructures is consistent with how endogenous
biochemicals are produced enzymatically in vivo, i.e., from precursors with similar
and/or overlapping structures.
Here, I present BioSM, a molecular classifier that can identify endogenous mammalian biochemical structures contained within chemical structure space. BioSM uses
the structures of known endogenous mammalian biochemical compounds as scaffolds
to aid in the classification process, as opposed to other works that use fragments
of known structures. The graph-based method implemented within BioSM can also
be expanded to predict metabolic pathways since it links a set of annotated scaffold
structures to each candidate structure.
In the empirical evaluation of BioSM, I initially focused on a curated set of endogenous human biochemicals obtained from the KEGG/LIGAND database to represent
the scaffolds list. The chemical space of non-biological compounds was approximated
by a randomly selected set of compounds from the Chembridge and Chemsysnthesis
chemical databases. Since structurally similar molecules tend to have similar properties [89], I use a graph matching algorithm to identify compounds that are structurally
similar to those in our scaffolds list. The classification method is based on a novel
scoring scheme that combines all matches of scaffolds to substructures of a candidate
compound as well as matches of the candidate compound’s structure to substructures
of the scaffolds. I was also interested in determining whether increasing the number
of scaffolds (i.e., increasing our representation of biochemical structure space) would
improve model sensitivity and specificity. Therefore, the initial KEGG scaffolds list
was supplemented with 2,362 curated compounds from HMDB and HumanCyc and
the assessment experiments were repeated.
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4.2

Computational Algorithm

Marvin [90], a chemical structure processing software, was used to generate canonical
SMILES (Simplified Molecular-Input Line-Entry System) [91] from structure data files
(.sdf) for all compounds described in this chapter. The Small Molecule Sub-graph
Detector (SMSD) Toolkit [92] was used to carry out molecule similarity searches.
SMSD is a Java based software library for finding the maximum common sub-graph
between small molecules using atom type matches and bond sensitivity information.
In this work, two molecular structures match if and only if the smaller structure was
an exact substructure (atom and bond types) of the larger structure being compared.
If two molecular structures r and q were found to be a match, their similarity score
is defined by
Sc =

AC(r)
AC(q)

(4.2.1)

where AC(r) represents the total number of atoms in the substructure, r, and AC(q)
represents the total number of atoms in the superstructure, q. Clearly, a candidate
molecule may match more than one scaffold structure, resulting in several similarity scores computed for each candidate compound. Initially, the highest similarity
score was selected to represent the degree of biochemical similarity between scaffold
structures and the candidate compound’s structure. However, it was observed that
multiple scaffolds could match different substructures of the candidate, significantly
strengthening the evidence that the candidate compound is an endogenous mammalian biochemical. Thus, I developed a ”union scaffold structure” approach that
incorporates all scaffolds matching a candidate compound’s structure and serves to
reduce bias that might exist due to overlap among scaffolds.
This representation provides a quantitative assessment of a candidate compound’s
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Figure 4.2.1: Matching a candidate structure (panel A) with 4 different scaffolds (panels B1- B5; note that scaffold B2 = scaffold B3) as substructures and the similarity
score of each match. The union scaffold structure incorporating all scaffold matches
is shown in panel C.
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overall ”biochemical coverage”. Figure 4.2.1 illustrates BioSM’s scaffold matching
process and shows how scaffolds are mapped onto the candidate structure to generate
the union scaffold structure. When multiple matches exist, BioSM incorporates each
one into the union scaffold structure being generated (Figure 4.2.1, matches B2 and
B3). Please note that a disjoint union scaffold structure may be generated if matching
substructure scaffolds do not overlap. Once a union scaffold structure is mapped to
a candidate structure, a similarity score, known as the union-scaffold score (US), is
computed using equation 4.2.1 with the candidate structure as the superstructure
and the union scaffold structure as the substructure.
I considered using the number of scaffolds that match a candidate structure as
an optional scoring parameter. It was realized, however, that this approach would
make BioSM’s predictions biased depending on the over or under abundance of any
particular group of structures in the scaffolds list. Knowing that our scaffolds list is
incomplete, since not all endogenous mammalian biochemical compounds are known,
it was decided not include the number of scaffold matches in a candidate compound’s
score.
I also recognized that some candidate structures may be small and thus have
very few scaffolds matching as substructures. Obviously, larger candidate compounds
have a better chance of matching substructures in the scaffolds list. Accordingly,
the method was modified to match and score scaffolds that are superstructures of
a candidate structure as well as those that are substructures. This approach seems
intuitive since many biochemical compounds are produced enzymatically (i.e., products) from larger precursor scaffolds (i.e., substrates) via biochemical pathways [93].
If a scaffold is found to be a superstructure of a candidate structure, a similarity score
is computed using equation (1). In addition, a candidate compound may be a sub-
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Figure 4.2.2: Matching a candidate structure (panel A) with 2 scaffolds (panels B1
and B2) as superstructures and the similarity score of each match. The scaffold
structure with the highest similarity score (scaffold B2) is selected.
structure of several scaffolds as shown in Figure 4.2.2. In that case, the scaffold with
the highest similarity score is selected, and that score is used as the superstructure
score.
Hence, a candidate compound can have a score of zero (when no matches are
found), a union scaffold score, a superstructure score, or both. In order to have
one value represent the structural match of a candidate compound to the biochemical scaffold structures, we combined the union scaffold and superstructure scores in
two different ways. In the first approach, referred to as the Sum of Scores (SS), we
obtained a candidate’s overall score by adding the union scaffold score to the super-
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structure score. In the second approach, referred to as the Maximum Score (MS),
the candidate’s score was the larger of the union scaffold score and superstructure
score. Figure 4.2.3 shows an overview of the general flow of BioSM and an illustrative
example.

4.3

Datasets

4.3.1

Chemical Space Definition

• Biological Dataset (Scaffolds List): The KEGG database served as the
source of the first set of endogenous mammalian scaffolds used in this study.
These scaffolds were selected based on their inclusion within at least one of
63 known KEGG mammalian pathways (scaffold pathway and metabolic class
information is given in Table 4.3.1). However, some compounds were excluded
from the final scaffold list. Compounds with elements other than C, H, N, O,
P and S are typically found only in marine organisms and extremely rare in
mammals. Hence, we decided to treat these compounds as non-mammalian
compounds and eliminated them (59 compounds). Molecules with a molecular
mass less than 50 Da (12 compounds) were removed. Fifty nine compounds
with any atom type other than C, H, O, N, S and P were eliminated as were
compounds that had duplicate structures (174 compounds), or were polymers
(223 compounds). Additionally, we eliminated compounds that did not have a
formula associated (27 compounds) and all charged structures (11 compounds)
except those in which the charge was due to quaternary amines or sulfonium
ions. This curation resulted in a final list of 1,565 mammalian scaffolds (KEG-

35

Figure 4.2.3: (A) General flow of BioSM and (B) an example showing how the union
scaffold structure and superstructure scaffold are used in the prediction process based
on 5BSS.
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Gscafs) for our initial representation of biochemical structure space.
• Non-Biological Dataset (Synthetic compounds List): The Chembridge
and Chemsynthesis databases, comprising synthetic compounds for chemical
synthesis and drug screening and design, were chosen to represent non-biological
chemical space. A set of 29,207 compounds was downloaded from the Chemsynthesis database on 7/18/2011 and a set of 760,517 compounds was downloaded from the Chembridge database on 7/20/2011. Because Chemsynthesis and Chembridge databases mainly contain compounds with low molecular
weights, a value of 700 Da was set as the maximum molecular weight of candidate compounds included in this study. Accordingly, 177 KEGG compounds
(with masses greater than 700 Da) were eliminated from any testing set throughout this study and were only used for superstructure scaffold matching. This
mass restriction was enforced to ensure that any compound with a mass range
50 – 700 Da was equally likely to be biological/non-biological and thus discrimination would be based solely on structure. Similar to KEGGscafs, the
combined synthetic set of compounds was curated by removing all compounds
containing elements other than C, H, O, N, S and P (297,721 structures), organic salts (3,496 structures), charged compounds (39,170 structures), duplicate
compounds (153 structures), and compounds with molecular mass less than 50
Da (8 structures). Additionally, we removed 127 compounds that were identical
to compounds in KEGGscafs. This curation resulted in a final set of putative
non-biological compounds consisting of 483,615 structures.
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Pathway Class
Carbohydrate
Metabolism
(CM)

Pathways
per Class
15

Energy
Metabolism
(EM)
Lipid
Metabolism
(LM)

1

Nucleotide
Metabolism
(NM)
Amino
Acid
Metabolism
(AM)

2

Metabolism of
Other
Amino
Acids (OAM)
Metabolism
of
Cofactors
and
Vitamins
(MCV)
Metabolism
of
Terpenoids
and Polyketides
(MTP)

3

16

13

12

1

Pathway KEGG IDs
ko00010,
ko00020,
ko00030
,ko00040, ko00051, ko00052,
ko00053,
ko00500,
ko00520,
ko00562,
ko00620,
ko00630,
ko00640, ko00650, ko00660
ko00190

ko00061,
ko00062,
ko00072,
ko00100,
ko00121,
ko00140,
ko00564,
ko00565,
ko00591,
ko00592,
ko01040
ko00230, ko00240

ko00071,
ko00120,
ko00561,
ko00590,
ko00600,

Compounds
per Class
293

10

430

137

ko00250,
ko00260,
ko00270,
ko00280,
ko00290,
ko00300,
ko00310,
ko00330,
ko00340,
ko00350,
ko00360,
ko00380,
ko00400
ko00410, ko00430, ko00480

502

ko00130,
ko00670,
ko00730,
ko00740,
ko00750,
ko00760,
ko00770,
ko00780,
ko00785,
ko00790, ko00830, ko00860
ko00900

296

69

26

Table 4.3.1: Pathway classes and individual pathways included in the study.
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4.3.2

Non-Biological Subsections (NBS)

In addition to these non-biological compounds, we empirically derived a set of nonbiological substructures (NBS) which are not commonly found in mammalian biochemical compounds [94]. The NBS list was checked against KEGGscafs. If an NBS
was found to be part of a compound in KEGGscafs, the NBS was removed. This
resulted in 35 substructures in the final NBS list (Tables 4.3.2 and ??). The NBS list
was used as an initial filter in the identification process. If a candidate compound
was found to contain at least one NBS it was predicted to be non-biological.

Table 4.3.2: List of Non-biological substructures (NBS)
#

NBS SMILES

1

C=S

2

S=O

3

S(=O)(=O)

NBS Structure

Exceptions
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Table 4.3.3: List of Non-biological substructures (NBS)
#

NBS SMILES

4

NBS Structure

#

NBS SMILES

C1=CC=C1

5

C1C=C1

6

C1C2C1C2

7

C1CC=C1

8

C1CC1

9

P1PP1

10

S1SS1

11

N1NN1

12

C=C=C

13

[N+](=O)[O-]

14

N=[N+]=[N-]

15

NNN

16

OOO

17

SSS

18

C=P

19

N=O

20

N=P

21

N=S

22

P=P

23

P=S

24

S=S

25

NS

26

CON

27

OON

NBS Structure

40

Table 4.3.3: List of Non-biological substructures (NBS) - Continued
#

NBS SMILES

28

#

NBS SMILES

PON

29

NON

30

SON

31

PP

32

PS

33

SN

34

SO

35

C#N

4.3.3

NBS Structure

NBS Structure

Training Data

From the selected set of 1,565 KEGGscafs, there were 1,388 compounds with molecular weights in the range 50 – 700 Da. These were used as the training set for our
method. A set of 1,388 synthetic compounds, selected from the synthetic compounds
dataset to match the mass distribution of the 1,388 biological set, was used to represent non-biological chemical space. Synthetic compounds containing one or more
NBS were not used for training since BioSM applies the NBS filter before the scaffolds
matching step.

4.3.4

Prospective Validation Sets

To estimate the performance of our predictive model, five external validation sets
were used; one set of drugs, two sets of putative human metabolites, one set of plant
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secondary metabolites, and one set of synthetic compounds. Figure 4.3.1 shows the
mass distribution of the compounds in each validation dataset. For each dataset,
any compound identical to any of KEGGscafs was removed. Also, structures found
in more than one dataset were removed from all datasets except one, as explained
below. The following is a description of the five datasets:
1. A dataset which contained 7,036 compounds obtained from DrugBank version
3.0 downloaded on 01/18/2012, combined with a set of 5,390 structures obtained
from the 1989 USAN and the USP Dictionary of Drug Names, was used as a drug
dataset. Salts, mixtures, compounds containing elements other than C, H, N,
O, S, and P; duplicate structures and compounds with molecular weight outside
the 50 – 700 Da range were removed resulting in a set of 3,895 compounds.
2. I used compounds from HMDB version 2.5, downloaded on 7/15/2012, to represent human metabolites. Out of the 8,534 molecules in that set, 174 compounds
contained elements other than C, H, N, O, S, and P; 4,209 molecules were outside the considered mass range (50 – 700 Da) and 133 compounds had duplicate structures. Additionally, 1,138 molecules were eliminated because they
were found in KEGGscafs and 132 were found in the drug dataset. Finally,
all charged structures except those in which the charge was due to quaternary
amines or sulfonium ions were eliminated. This resulted in an independent
dataset of 2,563 putative human metabolites.
3. I downloaded a set of 2,396 compounds from HumanCyc version 16.0 on 5/24/2012
to represent another dataset of putative human metabolites. A curated set of
158 compounds were available for testing after eliminating compounds containing elements other than C, H, N, O, S, and P (111 compounds), those not in the
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Figure 4.3.1: Mass Distribution of compounds in the validation datasets in 50 Da
bins.
mass range 50 – 700 Da (289 compounds), compounds found in KEGGscafs (198
compounds), charged compounds (792 compounds), duplicate structures (283
compounds), polymers (368 compounds), drugs (28 compounds), and HMDB
compounds (169 compounds).
4. A dataset of 2,829 secondary plant metabolites [95], as specified by KEGG, was
downloaded on 6/25/2012 to represent plant structures. A total of 2,416 compounds remained after removing compounds present in KEGGscafs (75 compounds), drugs (54 compounds), compounds not in the mass range 50 – 700 Da
(217 compounds), compounds containing elements other than C, H, N, O, S,
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and P (10 compounds), and compounds with charges (57 compounds).
5. A fifth dataset of 458,207 compounds from the Chembridge and Chemsynthesis
databases, not used in training the model, were used as a synthetic compound
test set. The same curation steps described above were used for these compounds.
In addition to these five validation datasets, we classified a random set of compounds
taken from the PubChem chemical database. On 12/15/2011, 30,142,651 compounds
were downloaded from PubChem. I eliminated 1,003,580 compounds with molecular masses not in the range of 50 – 700 Da. Further, 13,171,123 compounds that
contained elements other than C, H, O, N, S, P were eliminated. Three replicate
datasets, each containing approximately 320,000 compounds, were randomly chosen
from the remaining 15,967,948 PubChem compounds resulting in a total of 959,420
molecules. Further curation resulted in the elimination of 7,280 compounds with
duplicate structures, 67,449 compounds with charges and 12 compounds that had
disconnected structures. This resulted in three random samples totaling 883,199
test molecules. It should be noted that there was no attempt to remove compounds
present in any of the other validation sets from the PubChem dataset. The PubChem
dataset was intended to be a random sampling (other than curation requirements) of
PubChem compounds.

4.3.5

Extended Scaffolds List

In order to determine whether BioSM’s prediction accuracy would improve if the
number of scaffolds was increased, we compiled an updated scaffolds list of 3,927
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compounds (referred to as KHHscafs; KEGG, HMDB, and HumanCyc Scaffolds List)
using our initial KEGGscafs, plus additional compounds from the HMDB and HumanCyc databases. Only non-redundant compounds from HMDB and HumanCyc
predicted to be endogenous mammalian biochemical compounds by BioSM using
KEGGscafs were included in KHHscafs. This list consisted of the original 1,565
KEGGscafs, 2,273 compounds from HMDB and 89 compounds from HumanCyc. A
set of compounds from the synthetic dataset (randomly selected to match the KHHscafs mass distribution) were chosen to represent non-biological compounds. I then
used the same cross validation framework and scoring methods described earlier for
KEGGscafs. BioSM using KHHscafs was used to analyze the following independent
datasets:
1. the drug dataset described above (3,894 compounds),
2. the plant secondary metabolites dataset (2,354 compounds) after eliminating
62 compounds found in the KHHscafs,
3. compounds from the synthetic dataset (374,143 Chemsynthestis and Chembridge compounds) not used in training BioSM, and
4. one of the randomly generated Pubchem datasets (294,671 compounds).
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4.4
4.4.1

Results and Discussion
Selection of Candidate Scoring Methods by CV

In this thesis, the nested CV framework defined in 3.1.2 was used to evaluate the
performance of the proposed prediction methods. Specifically, parameter tuning was
performed by executing 5-fold CV on the training data and the classification accuracy
was empirically assessed using 2-fold CV on the testing data. Compounds in the
scaffolds list and an equal number of atom-matched non-biological compounds were
individually divided randomly into two halves: one half for model training and the
other half for model testing. The training half, comprised of 711 biological and 711
non-biological compounds, was further randomly split into k = 5 roughly equal parts.
Thus, the 711 biological compounds as well as the 711 non-biological compounds were
divided into 5 random parts. One part from the biological data along with one part
from the non-biological data were used to evaluate classification accuracy of models
trained on the remaining (k − 1) parts of the biological data as scaffolds. For the
results of each training fold, the score where SEN S = SP EC was recorded as the
cutoff threshold of that fold. This process was repeated 5 times to insure that each
of the 5 parts was evaluated.
Five-fold CV was used to determine bin boundaries ensuring that each bin had
approximately the same number of compounds, as well as independent score threshold
values for each bin. Both threshold scores and bin boundaries obtained from each of
the 5 training folds were averaged then applied to the testing fold.
Several methods for scoring a candidate compound were examined in this CV
analysis. Specifically, the US reflects the value of equation (1) having the candidate
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compound as the superstructure and the union scaffolds as the substructure, SS reflects the sum of the union scaffold score and the superstructure score, and the MS
reflects the larger of the union scaffold score and superstructure score. In preliminary
experiments we noted that the molecular weight of a compound had an impact on
its final score. This is because smaller compounds are more likely to match larger
scaffolds; larger compounds more likely to match smaller scaffolds and compounds
of intermediate size could match both smaller and larger scaffolds. Therefore, we
chose to split the set of test compounds into 5 mass bins. Five-fold CV was used to
determine bin boundaries ensuring that each bin had approximately the same number of compounds, as well as independent score threshold values for each bin (as
explained in 3.1.2). Both threshold scores and bin boundaries obtained from each of
the 5 training folds were averaged before applying BioSM to the testing fold. Thus,
the sum of threshold values obtained from each fold divided by the number of folds
(5) would be the averaged threshold score applied by BioSM to the testing fold. I
refer to classification obtained by applying the three scoring methods discussed above
with independent threshold values for each of the 5 bins as 5-Bin Union-scaffold
Score (5BUS), 5-Bin Sum of Scores (5BSS), and 5-Bin Maximum Score (5BMS),
respectively.
The accuracy measures explained above were used to compare results generated
from 15 CV experiments for each of the scoring functions (US, MS, SS, 5BUS, 5BMS,
and 5BSS) as shown in Table 4.4.1. An ANOVA test was carried out to check for
statistical significance between the 6 scoring methods (see section 3.2 for more details).
ANOVA results indicated no statistically significant difference between any of the 6
methods (P >0.05). However, 5BSS accuracy was consistently higher than the other
methods on all measures and thus was selected as the scoring method for all remaining
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experiments.
It is noticeable (Table 4.4.1) that the sensitivity of the model in the CV experiments is relatively low. As explained in the methods section, in each CV experiment
only half of the KEGGscafs were used for training the model and the other half were
used for testing. Thus, a candidate could be predicted to be non-biological because
there were no scaffolds in the randomly selected training set to match it in that
specific experiment.

Mean
StdDev
Mean
SPEC
StdDev
Mean
PPV
StdDev
Mean
MCC
StdDev
Mean
F Score
StdDev
SENS

Structure Scoring Methods
US
MS
SS
5BUS
0.77
0.78
0.78
0.76
0.02
0.02
0.02
0.03
0.71
0.71
0.72
0.71
0.04
0.04
0.04
0.04
0.73
0.74
0.74
0.73
0.03
0.03
0.03
0.04
0.49
0.5
0.5
0.47
0.05
0.05
0.05
0.05
0.75
0.75
0.75
0.74
0.02
0.02
0.02
0.02

5BMS
0.77
0.03
0.71
0.04
0.73
0.03
0.48
0.05
0.75
0.02

5BSS
0.79
0.02
0.73
0.04
0.75
0.03
0.51
0.04
0.76
0.02

Table 4.4.1: Mean and standard deviation of accuracy measures obtained for 15 cross
validation experiments using 6 different scoring methods and KEGGscafs (N = 1,565
compounds)

4.4.2

Leave-One-Out Cross Validation Experiments

Using the averaged meta-parameters determined by CV (as explained in 3.1.3), I
carried out a set of LOOCV experiments on the N = 1, 388 structures (with masses
between 50 and 700 Da) in our reference scaffolds database as an additional method of
evaluating the accuracy of BioSM in predicting endogenous mammalian biochemical
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structures. N experiments were performed and for each experiment, N -1 compounds
(plus 177 KEGG compounds with masses 700 – 1200 Da) were used as scaffolds and
the remaining compound was treated as an unknown. This allowed the use of all
but one scaffold in the prediction process. As a result, BioSM annotated 95% of the
compounds as being biochemical.

4.4.3

Prospective Validation

Five prospective datasets (drugs, plant secondary metabolites, 2 independent human
metabolite datasets, and a synthetic molecule dataset) were classified by BioSM using the 5BSS method. The compounds in each dataset were split into 5 bins (mass
range/bin determined as described in the CV experiments) and the percentage of
biochemical predictions per bin was computed (Figure 4.4.1). For the sake of comparison, the results from the LOOCV experiments with 1,388 KEGG endogenous
metabolites (described above) are also included in Figure 4.4.1. It is observed that
the prediction accuracy for KEGG compounds (LOOCV results) is uniform across
all mass bins. For the other datasets compounds in the mass range 287 – 700 Da
(bins 4 and 5) tended to have a higher probability of being predicted as endogenous
mammalian biochemical structures. This was especially true for the HumanCyc compounds, plant metabolites and drugs. The overall results (Table 4.4.3) show that
out of the 2,563 HMDB molecules, 89% were predicted to be biochemcal structures.
However, only 58% of HumanCyc compounds were predicted to be biological. Visual examination of the HumanCyc structures predicted to be non-biological showed
that many of them are indeed non-biological. For example, anthrazene, triazene and
compounds with cyclopropane rings are included in the list (these non-biochemical
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structures are given in the supplementary material). Thus, the above results are consistent with the intent of the HMDB and HumanCyc databases to include compounds
that are found in humans, however, these are not necessarily endogenous mammalian
biochemical compounds. For the 2,416 plant compounds, 72% were predicted to be
biochemical. Although this high percentage might seem initially surprising given that
we are using mammalian scaffolds to represent biochemical space, this result is consistent with current biochemical and evolutionary data suggesting that plant secondary
metabolites and mammalian biochemicals (i.e., our KEGGscafs) share multiple conserved biochemical pathways and thus an overlapping biochemical phylogeny [96].
Interestingly, only 1% of the plant secondary metabolites matched one or more superstructure scaffolds; and those plant compounds were found to have relatively small
molecular weights (116 - 299 Da). This suggests that plants have expanded upon conserved biochemical pathways to produce compounds containing unique combinations
of common scaffolds; and these unique combinations are not substructures of known
mammalian scaffolds.
Forty eight percent of 3,895 drug structures were predicted to be endogenous mammalian biochemical structures. These results are very similar to those found earlier
by Peironcely et al. using a similar drug dataset [87]. It is perhaps not surprising that
approximately half of the drugs were predicted to be endogenous biochemical structures since many are derived from natural products [51]. In contrast, only 29% of the
synthetic compounds were predicted to be endogenous biochemical structures. By
chance, synthetic compounds may be structurally similar to biochemical compounds.
Indeed, as mentioned previously, we found 127 compounds that had to be removed
from the synthetic data set prior to cross validation because they were identical to
compounds in KEGGscafs.
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Figure 4.4.1: Biological predictions within each mass bin for each dataset using KEGGscafs. 5BSS bin threshold values (thr) are also displayed.*LOOCV results.
In addition to these five prospective datasets, three random samples of approximately 294,000 compounds (883,199 total) from PubChem were tested. Thirty-four
percent (0.02%) of these were predicted to be biochemical. This suggests that the
Pubchem database contains mostly non-biological compounds. Thus, for metabolomics
studies where identification of unknown endogenous biochemicals is the primary goal,
BioSM would facilitate more efficient use of large chemical databases such as PubChem by removing non-biological candidate compounds from further consideration.
For example, BioSM will be incorporated into MolFind [66], a recently described
program that aids in the identification of unknown compounds detected in biological
samples by LC/MS. Table 4.4.2 shows the detailed predictions results for each of the
PubChem random samples as well as the average and standard deviation. Next, we
evaluated the distribution of candidate scores regardless of compound mass (Figure
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4.4.2) for each prospective dataset. PubChem compounds, synthetic compounds, and
compounds in the drug dataset have a large number of compounds (31%, 32%, and
25% respectively) with a candidate score of zero. After eliminating compounds with
a zero score due to NBSs (Table 4.4.2) we found that 8% of Pubchem compounds,
10% of the synthetic compounds and 9% of the drug compounds had no structural
similarity with any of our scaffolds. It is also clear in Figure 4.4.2 that Pubchem
compounds and synthetic compounds have very similar candidate score distributions.
PubChem Number
Random
of ComSet
pounds

1
2
3
Average
Std Dev

294,651
293,885
294,643
294,393
439.96

Predictions

NonBiological
(NBSs)
23.62%
23.62%
23.65%
23.63%
0.0002

NonBiological
(5BSS)
42.37%
42.36%
42.30%
42.34%
0.0004

Biological
(5BSS)
34.01%
34.02%
34.06%
34.03%
0.0002

Table 4.4.2: Prediction results for 3 random PubChem datasets using the 5BSS classifier and KEGGscafs.

A candidate score greater than 1.0 can only be achieved if the candidate compound has at least one matching substructure scaffold and at least one matching
superstructure scaffold. Figure 4.4.2 shows that 82% of the KEGG endogenous compounds, 54% of the HMDB compounds and 31% the HumanCyc compounds have
a scores between 1 and 2. Only a few of the drug, plant, PubChem and synthetic
compound structures have candidate scores in that range (9%, 7%, 2%, and 1% respectively). As mentioned earlier, only about 1% of the plant compounds matched
one or more superstructure scaffolds. Thus, of the 7% of plant compounds with scores
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between 1 and 2, approximately 6% of these had a score of 1. Using KEGGscafs, the
largest threshold value over all 5 bins was 0.89. Therefore any compound, regardless
of its mass, with a score of greater than 0.89 would be annotated as an endogenous
mammalian biochemical compound.

NonBiological
(5BSS)
10%

Biological
(5BSS)

2,563

Prediction
NonBiological
(NBSs)
1%

2,416

0%

28%

72%

158
3,895
458,207
959,420

7%
16%
21%
22%

35%
36%
50%
46%

58%
48%
29%
32%

Number of
Compounds

Type

HMDB
Plant
Secondary
Metabolites
HumanCyc
Drugs
Synthetics
PubChem

89%

Table 4.4.3: Predictive results using the 5BSS classifier for 6 different datasets using
KEGGscafs.

4.4.4

Extended Scaffolds List

The analysis above was based on using BioSM and the curated set of 1,565 KEGGscafs. This assumes that these 1,565 structures provide a complete (or nearly complete) representation of mammalian biochemical structure space. Thus, an important
question is whether a larger scaffold list (larger biochemical structure space) would
significantly change the results presented above. After updating the scaffolds list to
3,927 compounds (KHHscafs described above), I followed the same process for finding
the best scoring method, cutoff values, and bin masses using 15 CV experiments with
3,750 training scaffolds (3,927 – 177 = 3,750) in the 50 - 700 Da mass range. For the
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non-biological set we selected a random set of structures from the Chembridge and
Chemsynthesis databases which matched the mass distribution of the 3,750 training
KHHscafs. Note that since this non-biological set was chosen at random from our curated dataset of 483,615 synthetic compounds, it is not identical to the non-biological
set used for CV of KEGGscafs. Table 4.4.4 shows the average accuracy measures
of the 15 CV experiments for US, MS, SS, 5BUS, 5BMS and 5BSS methods. An
ANOVA of the results in Table 4.4.4 indicated statistically significant (P <0.05) differences between SPEC and PPV for one or more of the 6 scoring methods. Having
the highest SPEC (0.75) and PPV (0.83), 5BSS was selected as the scoring method
for BioSM when using KHHscafs to reanalyze the various datasets as described above.
A further ANOVA of the 5BSS CV results for KEGGscafs and KHHscafs showed a
statistically significant (P <0.05) difference between all measures.

SENS
SPEC
PPV
MCC
F Score

Mean
StdDev
Mean
StdDev
Mean
StdDev
Mean
StdDev
Mean
StdDev

Structure Scoring Methods
US
MS
SS
5BUS
0.84
0.84
0.84
0.83
0.01
0.01
0.01
0.02
0.72
0.72
0.72
0.73
0.01
0.01
0.01
0.01
0.81
0.81
0.81
0.82
0.01
0.01
0.01
0.01
0.56
0.56
0.57
0.56
0.02
0.02
0.02
0.02
0.82
0.82
0.83
0.82
0.01
0.01
0.01
0.01

5BMS
0.84
0.02
0.73
0.01
0.82
0.01
0.57
0.02
0.83
0.01

5BSS
0.83
0.02
0.75
0.01
0.83
0.01
0.58
0.02
0.83
0.01

Table 4.4.4: Average and standard deviation of accuracy measures obtained for 15
cross validation experiments using 6 different scoring methods and the KHHscafs (N
= 3,927 compounds).

Figure 4.4.3 shows the results of LOOCV as well as the results of the prospective
datasets per mass bin. Ninety six percent of the 3,750 KHHscafs were correctly pre-
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Figure 4.4.2: Frequency distribution of candidate scores for each dataset. 5BSS
threshold values for each of the 5 bin masses are given in Figure 4. *LOOCV results.
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Figure 4.4.3: Biological predictions within each mass bin for each dataset using KHHscafs. 5BSS bin threshold values (thr) are also displayed. *LOOCV results.
dicted as biological using a LOOCV. Even though this value is high, four percent of
our scaffolds were still incorrectly annotated (these structures are found in supplementary material). In many cases, we noted that these false negatives were because
BioSM requires an exact match between the scaffold and the candidate. This was
particularly problematic for predicting specific classes of compounds. For example,
lipids with a double bond in the middle of the structure were poorly predicted by
BioSM since there may not be scaffolds that match either side of the double bond.
I explored using scaffold matching without the requirement of exact bond matching; however, the specificity of the system was negatively affected. It is important
to note that bin masses and cut-off thresholds changed after running CV with the
updated KHHscafs. This explains why some compounds predicted to be biological
using KEGGscafs might be predicted to be non-biological using KHHscafs or vice
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versa. Although the 96% sensitivity suggested by our LOOCV analysis is quite good,
a possible approach to further improve BioSM would be to expand the set of scaffolds
by using enzyme reaction information (oxidation and or reduction reactions for example). In this case, not only would BioSM be searching for exact structure matches
between scaffolds and candidate compounds, but also among putative metabolites of
those scaffolds. BioSM will apply a set of applicable enzyme reactions to a candidate compound; if any of the metabolites produced were found to be an endogenous
mammalian biochemical compound by BioSM then the candidate is also biochemical.
Using KHHscafs, BioSM predicted 74% of the 2,354 plant compounds, 42% of
the 3,894 drug compounds, 26% of the 374,143 synthetic compounds and 25% of
the 294,671 random Pubchem compounds as biological. It is important to point out
that this 25% value for PubChem does not include compounds that were eliminated
during the initial curation steps (mass range requirement, compounds with elements
other than C, H, N, O, P, S, stereoisomers, salts and disconnected structures). Thus,
starting with approximately 29,000,000 PubChem compounds with MIMW between
50-700 Da, it was estimated that approximately 3,680,000 (13%) of these would be annotated as mammalian biochemical compounds using our curation steps and BioSM.
Figure 4.4.4 shows the distribution of candidate scores from each dataset regardless
of compound mass.
Figure 4.4.5 illustrates the percentage of molecules predicted to be biological by
BioSM using KHHscafs versus KEGGscafs in each of the prospective datasets. Although sensitivity, specificity, MCC, PPV and F score are all significantly higher
when using KHHscafs, overall, the percentages predicted to be biological are very
similar using the two sets of scaffolds. Thus, it is unlikely that the use of additional
scaffolds will significantly improve our representation of biochemical structure space
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Figure 4.4.4: Distribution of compounds based on their candidate scores using KHHscafs. *LOOCV Results.
as defined here, and that the model is reasonably robust. One could argue that the
2,362 added scaffolds may not have contributed appropriate biochemical structure
diversity since they were predicted to be biological using KEGGscafs. However, this
seems unlikely due to the large number of non-redundant structures added, and the
fact that all CV model parameters were significantly improved compared to KEGGscafs. Further slight improvements may still be possible by iteratively expanding
the scaffold list; notably, out of the 275 HMDB compounds classified as non-biological
using KEGGscafs, 91 of these were classified as biological using KHHscafs.
It is difficult to measure the accuracy of BioSM based on the results displayed
in Figure 4.4.5 as there is no definite answer as to whether or not each compound
in these datasets is actually an endogenous mammalian biochemical. Yet it is still
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Figure 4.4.5: Percentage of biological predictions in each data set using KEGGscafs
versus using KHHscafs. *Refer to LOOCV results when using the KEGGscafs dataset
(turquoise bar) and the KHHscafs (purple bar) as defined in the methods section
above.
interesting to see how BioSM classifies compounds from each dataset.

4.5

Conclusions

In this chapter, I described the development and validation of BioSM, a novel supervised classifier that uses endogenous mammalian biochemical scaffolds to predict
whether a candidate chemical structure is biochemical or synthetic. BioSM was able
to correctly classify 96% of 3,750 biochemical compounds in a leave-one-out cross
validation experiment. In addition, the results suggest that approximately 13% of
PubChem compounds are mammalian biochemicals. Thus, BioSM may be useful for
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searching large chemical databases in metabolomics applications where the number
of potential false positives is very large. Additionally, BioSM can place molecules in
the context of metabolic pathways since it can link potentially unknown biochemicals
to matched substructure and superstructure scaffolds for which metabolic pathways
are known.

Chapter 5
Efficient identification of
endogenous mammalian
biochemical structures

5.1

Introduction

BioSM’s limitations, granting its encouraging results, is its need to exhaustively search
all known biochemical structures to be able to make a decision about the candidate
compound under investigation which resulted in an undesirably high run time. In this
chapter, I introduce BioSMXpress. BioSMXpress was designed as an enhancement to
BioSM with the aim of making the least possible number of structure comparisons to
efficiently identify biochemical structures with the aid of a scaffolds list. BioSMXpress
decides if a candidate structure is biochemical based upon how similar that structure
is to any of the structures in the scaffolds list. BioSMXpress is a highly multi-threaded
desktop application written in Java.
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Similar to BioSM, two molecular structures are considered to be a ”match”, if
the smaller structure is an exact substructure (atom and bond types) of the larger
structure being compared. Also, the underlying cheminformatics functionality of
BioSMXpress is based on SMSD [92]. In addition to SMSD, BioSMXpress uses Marvin, a chemical structure processing software, to generate both the canonical SMILES
and atom counts from structure data files (.sdf) for all the compounds described in
this work.

5.2

Computational Algorithm

Here, I will introduce a tool that can efficiently identify small endogenous mammalian biochemical structures from the chemical structure space. First, I will start
by defining some notations followed by a detailed explanation of the computational
model behind BioSMXpress. Let cq be the molecular structure of a query compound,
S = s1 s2 . . . sn be a set of n small biological compounds (scaffolds). Let sx ∼ cq
indicate that scaffold sx is a substructure of candidate compound cq , and AC (sx )
represent the number of atoms in compound sx . Let minAC define the minimum
number of atoms required in a scaffold sy to identify cq as biological if cq ∼ sy . If two
molecular structures r and q were found to be a match, a similarity score (as defined
in equation 4.2.1) is calculated where r ∼ q. Based on a given substructure threshold
(subThr ), the minimum atom count is computed as

minAC = bAC (cq ) ∗subT hrc .

(5.2.1)
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Similarly, based on a given superstructure threshold (superThr ), BioSMXpress computes the maximum atom count,


AC (cq )
maxAC=
superT hr


.

(5.2.2)

 0 0
0
Finally, let S̄ = s1 , s2 , . . . , sl | l ≤ n be the scaffold list assigned to cq where S̄ ⊆
0 
0
S. A scaffold sx ∈ S is assigned to S̄ if and only if minAC ≤ AC sx ≤ maxAC.
Please note that each candidate structure with a different atom count is provided with
a different set of scaffolds in S̄. Once S̄ is populated with the appropriate scaffolds
for cq , BioSMXpress examines cq against each of those scaffolds. As soon as a match
(substructure or superstructure) is found, BioSMXpress predicts that cq is biological and terminates. Otherwise, it’s predicted to be non-biological. Values for subThr
and superThr are determined by cross validation as described in the following section.
Figures 5.2.1 illustrates a visual example of the BioSMXpress scaffolds selection and
ordering process.
In addition to that, BioSMXpress orders the potential scaffolds in S̄ such that
scaffolds with atom counts closer to the candidate atom count are examined first
followed by those with a larger atom count difference. In this case, once a match is
found the search terminates and it is guaranteed that this is the best possible match
(as a substructure or superstructure). Figure 5.2.2 shows an overview of the general
flow of BioSMXpress and an illustrative example.
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(a)

(b)

Figure 5.2.1: Scaffold selection and sorting Process. In this example, it is assumed
that the candidate compound (cq ) consists of 9 atoms and that subThr
 9  = 0.5 and
superThr = 0.51. Therefore, minAC = b9∗0.5c = 4 and maxAC= 0.51
= 18. (a)
The hashed scaffolds list with minAC and maxAC identified. (b) The sorted scaffolds
list consists of all the scaffolds with 9 atoms followed by those with 10 atoms followed
by those with 8 atoms and so on.
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Figure 5.2.2: (A) General flow of BioSMXpress and (B) an example showing how the
appropriate scaffolds list is populated.
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5.3

Datasets

I will briefly describe the source and nature of the datasets selected to train and validate BioSMXpress. Since these datasets will be used to compare between BioSMXpress
and BioSM in terms of prediction accuracy, I utilized the same datasets and followed
the same curation steps in 4.3.4.
In each dataset, compounds with any of the following characteristics were eliminated: (1) compounds with elements other than C, H, N, O, P and S; (2) compounds
with less than 4 atoms and more than 53 atoms (explained below); (3) compounds
that were polymers; (4) charged structures except those in which the charge was due
to quaternary amines or sulfonium ions; (5) compounds with duplicate structures;
and (6) compounds with disjoint structures.

5.3.1

Biological Dataset (Scaffolds list):

The KEGG database was chosen as the source of endogenous mammalian compounds.
The list of 1,564 mammalian scaffolds (KEGGscafs) defined in [94] were used to
represent the biochemical structure space in BioSMXpress. Each compound in the
scaffolds list comprises of a number of atoms from 4 to 80 atoms per compound.

5.3.2

Non-Biological Dataset (Synthetic compounds list):

The Chembridge (www.chembridge.com) and Chemsynthesis (www.chemsynthesis.com)
databases served as the sources of compounds representing the non-biological chemical space. These databases were selected because they comprise synthetic compounds
for chemical synthesis and drug screening and design. After curation, a set of 375,930
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structures represented the synthetic compounds list. Chemsynthesis and Chembridge
databases mainly contain compounds with low molecular weights (a maximum atom
count of 53 atoms per compound). Accordingly, 143 of the 1,564 KEGGscafs (with
atom count between 54 and 80) were eliminated from any testing set throughout this
study and were only used for superstructure scaffold matching. This restriction was
enforced to ensure that the sole discrimination between a compound being biological
or non-biological is based on the structure of a compound and not on the number of
atoms in that compound.

5.3.3

Training Dataset

A total of 2,842 compounds, with at least 4 atoms and at most 53, were used to
train and test our predictive model. Half of those compounds were obtained from
the scaffolds list (representing the endogenous mammalian chemical space) and the
other half from the synthetic compounds list (representing the non-biological chemical
space). The later molecules were randomly selected from the synthetic dataset to
match the atom count distribution of the 1,421 biological set.

5.3.4

Independent Datasets

To estimate the performance of our predictive model and compare it with that of
BioSM, four external validation sets were used: one set of putative human metabolites,
one set of plant secondary metabolites, one set of drugs, and one set of synthetic
compounds. For each dataset, any compound with a structure identical to any of
those in the scaffolds list was removed. Also, structures found in more than one
dataset were removed from all datasets except one. Molecules in each dataset had to
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satisfy both mass (50 – 700 Da) and atom count (4 – 53 atoms) constraints to allow
for a fair comparison between BioSMXpress and BioSM. Additionally, compounds
with at least one NBS (see 4.3.2) were eliminated. This decision was based on our
interest in comparing the core predictive models of BioSM and BioSMXpress since
in reality, NBS filters will be applied to both models before any scaffold comparisons
are involved.
The following is a brief description of the five datasets. Please note that the
numbers of compounds reported below refer to the datasets after curation. The first
dataset consisted of 2,329 compounds and was obtained from HMDB version 2.5
representing putative human metabolites. The second dataset consists of 2,416 secondary plant metabolites, as specified by KEGG, representing plant structures. The
drug dataset was represented by 3,282 compounds and was obtained from DrugBank
[71] version 3.0 and from the 1989 USAN and the USP Dictionary of Drug Names. A
randomly chosen set of approximately 46,203 molecules was from the National Center for Biotechnology Information’s (NCBI) PubChem database [67]. PubChem is
the largest freely accessible compound database currently available. Finally, a set of
374,509 compounds from the Chembridge and Chemsynthesis databases, not used in
training the model, were used as a synthetic compound test set.

5.4
5.4.1

Results and Discussion
Classification Methods Selection

Four classification methods were proposed for BioSMXpress specifically, the SSF
method which refers to finding a substructure scaffold match or a superstructure
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scaffold match in the sorted scaffolds list was utilized. SSSF refers to searching for
the best substructure scaffold similarity score (Scsub ), if existent, and the best superstructure scaffold similarity score (Scsuper ), if existent. It declares the candidate as
biological if Scsub + Scsuper ≥ sumT hr. From my experience with BioSM, I found
that distributing candidates into mass bins, with each bin having its own threshold
values, showed an improvement in the prediction quality. Thus, we decided to test if
the same concept applies here. I split the set of test compounds into five bins based
on the number of atoms per compound and used CV to evaluate the model. This
introduced two more methods, SSB and SSSB, similar to SSF and SSSF respectively,
except that there are independent thresholds assigned to each bin.
So, the CV training phase was used to record Scsub , Scsuper and the sum of scores
(Scsub + Scsuper ) of the training data and determine the cutoff thresholds, subThr,
superThr and sumThr where SENS = SPEC. Then the average thresholds of all five
training sets were used as the cutoff values when evaluating the CV testing data as
explained in 3.1.2.
I ran 15 CV experiments to evaluate the performance of each method. Some
accuracy measures defined in 3.3 were applied to each of the results of the 15 CV
experiments. The mean and standard deviation of the 15 experiments are displayed
in Table 5.4.1. The highest sensitivity of 90% was obtained by the SSF classifier.
At the same time, SSF suffered from the lowest specificity of 55% only. Another
observation is that the application of sumThr improved the specificity significantly,
82% (SSSB) and 71% (SSSF) versus 62% (SSB) and 55% (SSF) but affected the
sensitivity negatively (53% and 73%, respectively). SSB had the best MCC of 51%
and hence was selected as the method of choice for BioSMXpress with a sensitivity
of 86% and a specificity of 62%.
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5.4.2

Leave-One-Out Cross Validation Analysis

As an additional method to evaluate how well BioSMXpress can identify endogenous
mammalian biochemical structures using the SSB classifier, we carried out a set of
LOOCV experiments (defined in 3.1.3) using the SSB method with the averaged
subThr, superThr and bin boundaries determined by CV as explained in the Methods
section. Here, 1,421 experiments representing KEGG structures (with atom count
between 4 and 53 atoms/compound) were carried out. Please note that in every
experiment, the scaffolds list was composed of 1,420 compounds plus 143 compounds
(those with atom count between 54 and 80 atoms/compound) as the scaffolds list.
As a result, BioSMXpress annotated 94% of the 1,421 compounds as being biological
structures.
Using 1,387 scaffolds in a set of LOOCV experiments implemented by BioSMXpress
and BioSM independently were implemented and compared. These 1,387 compounds
were the scaffolds that satisfied the constraints of both BioSM and BioSMXpress
(mass in the range of 50 – 700 Da and number of atoms in the range of 4 – 53).
BioSM was capable of identifying 94.5% of the 1,387 scaffolds as biochemical structures while BioSMXpress identified 94.2%. Figure 5.4.1 shows the breakdown of the

SENS
SPEC
MCC

Mean
StdDev
Mean
StdDev
Mean
StdDev

SSF
0.90
0.02
0.55
0.04
0.41
0.03

SSSF
0.73
0.04
0.71
0.05
0.45
0.02

SSB
0.86
0.02
0.62
0.04
0.51
0.05

SSSB
0.58
0.03
0.82
0.03
0.48
0.05

Table 5.4.1: Mean and standard deviation of accuracy measures obtained for 15 cross
validation experiments using 4 different scoring.

70
results of this comparison with compounds binned by atom count.
BioSMXpress performed best when identifying compounds in the first bin (99%
positive identification of biochemical compounds) while BioSM was able to predict
only 92% of those compounds. On the other hand, BioSM’s highest performance was
achieved by predicting 96% of the compounds in the fourth bin while BioSMXpress
identified 88% of them. In general, Figure 5.4.1 indicates that BioSMXpress is better
at identifying biochemical compounds in the first and second bins (99% and 97%,
respectively), while BioSM is better at identifying biochemical compounds in the
fourth and fifth bins (96% and 94%, respectively). They both identify compounds in
the third bin with the same accuracy (95%).
A note worth mentioning is that in addition to the 1,387 scaffolds annotated,
BioSMXpress was able to positively identify 34 compounds in the scaffolds list that
were rejected by BioSM without classification due to mass restrictions (masses were
greater than 700 Daltons). This indicates that BioSMXpress has broadened the
range of compounds examined just by restricting the number of atoms in a candidate
compound versus its molecular mass.

5.4.3

Prospective Validation

Independent datasets containing plant secondary metabolites, drugs, independent human metabolites, synthetic molecules, and PubChem compounds were classified by
BioSMXpress. The compounds in each dataset were split into 5 bins (atom count
bins determined as described in the CV experiments) and the percentage of biochemical predictions per bin was computed (Figure 5.4.2). For the sake of comparison,
the results from the LOOCV experiments with 1,387 KEGG endogenous metabolites
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Figure 5.4.1: Biological predictions resulting from a set of LOOCV experiments by
BioSMXpress and BioSM with 1,387 KEGG compounds. Compounds were binned
by atom count.
(described above) are also included in the figure. It is observed that BioSMXpress is
capable of efficiently discriminating between mammalian structures in datasets such
as KEGG and HMDB compounds and non-mammalian ones such as those in the
Plant, Drug, Pubchem, and Synthetic compounds specifically for compounds with
atom count between 4 and 19 atoms per compound (Bins 1, 2, and 3). The averaged biological prediction of the first 3 bins was very high for the KEGG and HMDB
datasets (97% and 86%, respectively) and significantly low for the Plant, Drug, Pubchem, and Synthetic compounds datasets (35%, 39%, 26%, and 24%, respectively).
The results also show that compounds with 20 – 53 atoms from both the plant and
drug datasets tend to look more biological (84% and 69%, respectively). This might
seem initially surprising, but the plant dataset results are consistent with current
biochemical and evolutionary data suggesting that plant secondary metabolites and
mammalian biochemical structures share multiple conserved biochemical pathways
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and thus have an overlapping biochemical phylogeny. Similarly, since many drugs are
derived from natural products, it is not unexpected to find that 69% of the larger
compounds were predicted to be endogenous biochemical structures.

Figure 5.4.2: Biological predictions within each atom count bin for each dataset
using BioSMXpress. SSB bin threshold values (subThr and superThr ) are also displayed.*Representing LOOCV results.
Subsequently, the same datasets were also annotated by BioSM. Table 5.4.2 presents
a comparison of BioSM’s predictions versus those of BioSMXpress. The results indicate that 91% of the 2,329 HMDB molecules were correctly classified as endogenous
mammalian metabolites while 88% of them were identified by BioSM. Predictions
for the 2,416 plant metabolites by BioSMXpress and BioSM were comparable with
72% and 73%, respectively. As for the 3,282 drug compounds, 58% were predicted
to be biological by BioSMXpress versus 62% by BioSM. In contrast, only 25% of
the randomly selected 46,203 PubChem compounds were predicted as biological by
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BioSMXpress as opposed to 35% by BioSM.
In addition to these four prospective datasets, a set of 374,509 synthetic compounds (represented by Chembridge and Chemsynthesis compounds) were evaluated
by BioSMXpress and BioSM with 36% and 33% of these being predicted to be biochemical, respectively. Overall, the comparison in Table 2 shows that the biochemical
prediction percentages made by BioSM and BioSMXpress are practically comparable
except that BioSMXpress predicted 10% lesser compounds of the PubChem compounds as biological.
Dataset
HMDB Compounds
Plant Metabolites
Drug Compounds
PubChem Compounds
Synthetic Compounds

Number of Compounds
2,329
2,416
3,282
46,203
374,509

BioSM
88%
73%
62%
35%
33%

BioSMXpress
91%
72%
58%
25%
36%

Table 5.4.2: Predictive results using the SSB classifier for 6 different datasets.

5.4.4

Execution and CPU Time Comparison

Now that I have shown that the predictive performance of BioSMXpress is analogous
to BioSM, in this section we discuss their time performance. I used a high-end cluster
(http://becat.uconn.edu/hpc/) hosted by the School of Engineering and the Taylor
L. Booth Engineering Center for Advanced Technology (BECAT) at the University of
Connecticut to run and compare the performance of both BioSM and BioSMXpress.
I ran both classifiers with a set of randomly generated datasets as candidate datasets
for prediction. Each dataset was evaluated by both predictive models under the
same circumstances (same number of cluster nodes, threads, same scaffolds list, etc.)
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and the time for each model was recorded. I was also interested in comparing the
CPU time utilized by both BioSM and BioSMXpress. CPU time is the amount of
time for which a central processing unit (CPU) was used for processing instructions
of a computer program or operating system, as opposed to, for example, waiting
for input/output operations. Figure 5.4.3b shows the average CPU time utilized by
each of the classifiers when making predictions for each data set size (50 – 50,000
compounds). Similar to response time, BioSMXpress has outperformed BioSM by
utilizing an average of 7 times less CPU time. I generated multiple candidate datasets
with 50, 100, 500, 1,000, 5,000, 10,000, and 50,000 compounds. Each dataset was
composed of randomly selected compounds from a pool of all the independent datasets
used in this study as described in the Methods section. To ensure that the only factor
I am measuring is the number of compounds in a set regardless of the nature of the
compounds included, I generated multiple random datasets (specifically 3) with the
same number of compounds for each size required. So, I ran 3 groups each containing
50 randomly selected compounds, 3 groups of 100 compounds and so on, and then
reported the average response time of each group size. Figure 5.4.3a displays the
average run time of BioSM versus that of BioSMXpress when annotating datasets of
sizes 50 to 50,000 compounds as explained above.
Obviously, BioSMXpress impressively outperformed BioSM across all datasets.
BioSMXpress was 10 times faster than BioSM when analyzing 10,000 compounds.
Across all datasets examined, BioSMXpress provided an 8 times average speed up
over BioSM. Another interesting observation is that it takes BioSM an average of 6
minutes and 51 seconds to evaluate 1,000 compounds while it takes BioSMXpress an
average of 5 minutes and 8 seconds to evaluate 10,000 compounds (10 times more
compounds in less time).
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(a)

(b)

Figure 5.4.3: (a) Average runtime (in hh:mm:ss) needed to make predictions using
BioSM versus BioSMXpress. (b) Average CPU time (in seconds) for BioSM and
BioSMXpress when annotating sets of compounds of different sizes.
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This drastic difference in run time and CPU time can be explained by observing the number of scaffold comparisons required by each predictive model to make
a prediction about any given candidate compound. BioSM needs to compare the
candidate structure with each and every structure in the scaffolds list accumulating
scores and then finally comparing that score with a threshold to make a prediction.
BioSMXpress intelligently selects and sorts the scaffolds that would produce the highest match scores, based on the thresholds, if they were to match the candidate. Only
a portion of the scaffolds are added to the list that is actually used by BioSMXpress as
the scaffolds list and once a match is found the candidate is predicted to be biological
with no other computational steps further needed.

5.5

Conclusions

In this chapter, I described the development and validation of BioSMXpress, an efficient supervised cheminformatics tool that uses endogenous mammalian biochemical
scaffolds to predict whether a candidate chemical structure is biochemical or synthetic.
BioSMXpress is at average 8 times faster than BioSM without compromising the accuracy of the predictions. BioSMXpress was able to correctly classify 94% of 1,421
biochemical compounds in a set of leave-one-out cross validation experiment. Thus
BioSMXpress may be useful for searching large chemical databases in metabolomics
applications where the number candidates is extremely large as well as the number
of potential false positives in an efficient manner.

Chapter 6
Classifying Small Molecules into
Metabolic Pathways

6.1

Introduction

Metabolic pathways are characterized as a series of chemical reactions catalyzed by
enzymes connected in a way such that the reactants of one reaction are the products
of the previous one. Understanding these pathways is essential to understanding the
machinery of life [75]. The reconstruction of the metabolic network of an organism
based on its genome sequence is a key challenge in systems biology [97]. Predicting
which metabolic pathways are present in the organism based on the annotated genome
of the organism is a possible strategy to address this issue [76]. Such metabolic
pathways are selected from a reference database of known pathways. Other strategies
provide some data mining capabilities to correlate protein annotations to pathway
templates so that organism-specific pathways can be derived. Some of the commonly
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used tools include PathComp [98], Pathway Analyst [75], Rahnuma [99], Pathway
Tools [100], UM-BBD Pathway Prediction System [101], and PathPred [102].
Pathway prediction can involve predicting pathways that were previously known in
other organisms, or predicting novel pathways that have not been previously observed
(pathway discovery) [76]. The work addressed in this chapter is focused on methodologies that do the former, predicting pathways from a curated reference database.
A number of databases collecting biological pathway information are available
allowing broader exploration of metabolism. One of which is the Kyoto Encyclopedia of Genes and Genomes (KEGG) database [73]. KEGG contains a collection of
manually drawn pathway maps representing molecular interaction and reaction networks. Eleven major metabolic pathway classes that are strongly associated with
the biological functions of compounds are defined by KEGG as [103]: Carbohydrate Metabolism, Energy Metabolism, Lipid Metabolism, Nucleotide Metabolism,
Amino Acid Metabolism, Metabolism of Other Amino Acids, Glycan Biosynthesis and Metabolism, Metabolism of Cofactors and Vitamins, Metabolism of Terpenoids and Polyketides, Biosynthesis of Other Secondary Metabolites, and Xenobiotics Biodegradation and Metabolism, each of which contains several individual
pathways. Some compounds serve as intermediates in multiple pathways and appear
on multiple KEGG pathways.
New metabolic experiments combined with computational methods are likely to
reveal the structures of new metabolites that do not belong to any known metabolic
pathways. Placing these molecules in the context of known metabolic pathways would
aid in understanding their biological functions. It will shed the light at the presence of
yet unidentified gene products that may be catalyzing relevant reactions [93]. Thus,
the aim of this work is to develop and assess a model to predict the pathway classes
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and individual pathways that a given query molecule would lie closest to.
Primary attempts of correlating the similarities between metabolites with metabolic
pathways have been performed by Nobeli et al. [104]. Further investigations performed by Cai et al. [105] utilized functional group composition of compounds to
represent small molecules. They proposed a Nearest Neighbor Algorithm to map small
chemical molecules to the metabolic pathway class that they likely belong to. After
excluding all compounds that belonged to two or more metabolic pathway classes, a
set of 2,764 compounds from 11 major classes of metabolic pathways, obtained from
KEGG, were selected for the study. An overall prediction rate of 73.3% was observed.
Since the authors were focused on addressing the single-label classification problem,
their methods could not be used to deal with the ”multi-function” compounds, compounds that belong to more than one pathway class. Macchiarulo et al. [93] used 32
quantitative structure activity relationship descriptors to estimate the proximity of
any small molecule to a given pathway class. When classifying 681 small molecules
into 7 KEGG pathway classes using a random forest classifier [84], they reported an
average Matthews correlation coefficient of 0.73. They expanded their investigation
to predict individual pathways to which these small molecules would lie close to as
well. When classifying those metabolites to 52 individual KEGG pathways, they were
able to predict the correct pathways for only 31% of the molecules.
A multi-target model for predicting which of the 11 KEGG metabolic pathway
classes a query compound may be involved was proposed by Hu et al. [103]. The
model was built upon information of chemical-chemical interactions retrieved from
STITCH [106]; a database containing known and predicted interactions of chemicals and proteins derived from experiments, literature and other databases. In their
model, an interaction unit consists of two chemicals and their interaction weight (con-
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fidence score) representing the probability that the interaction occurs between the two
chemicals concerned. It was observed that the overall success rate obtained by the
method via the 5-fold cross-validation test on a benchmark dataset consisting of 3,137
compounds was 77.97%.
Gao et al. [107] extended Hu et al.’s work by integrating interactions among
chemicals and proteins. Their work included not only chemical-chemical interactions
but also protein-protein interactions and chemical-protein interactions, to predict
metabolic pathways in which small molecules and enzymes of yeast participate. The
data concerning protein-protein interactions was retrieved from STRING [108]. They
constructed a hybrid interaction network having small molecules and enzymes as
its nodes, and edges between two nodes if and only if there is data showing that
they can interact with one another. Results of the jackknife test, a leave-one-out
cross validation method, show that the first order prediction accuracy for 3,348 small
molecules was 77.12% and 92.05% for the 655 enzymes which does not reflect any
improvement over Hu et al.s approach.
One of the major limitations in the approaches proposed in [103, 107] is their
dependency on interaction information. Hu et al. reported that they were unable
to process 1,229 compounds due to the lack of interaction information with other
compounds within the dataset they were using.
In this chapter, I introduce TrackSM, a Bioinformatics tool designed to predict the
metabolic pathway class as well as the individual pathways to which small molecules
might be associated with, based only on their molecular structures. Small molecules
within a typical pathway tend to look similar as they are related to each other through
stepwise chemical transformations. TrackSM is guided by structural similarity information acquired from a set of compounds, hereafter referred to as scaffolds. In other
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words, TrackSM represents pathways using the scaffolds they comprise.

6.2

Computational Algorithm

In TrackSM, a query compound is predicted to belong to a metabolic pathway based
on how similar its chemical structure is to those structures associated with a given
pathway. TrackSM relies on the SMSD Toolkit [92] to carry out molecular similarity
searches.
In this chapter, I define two ways for matching molecular structures: Match100
and Match90. In Match100, two molecular structures are considered a match if and
only if the smaller structure is an exact substructure (atom and bond types) of the
larger structure being compared. Match90 considers two molecular structures as
similar if at least 90% of the smaller structure’s atoms match the larger structure
being compared. Regardless of the matching method, the similarity score between
two molecular structures is defined by
Two molecular structures r and q are found to be a match if and only if the smaller
structure, r, is an exact substructure (atom and bond types) of the larger structure,
q. Match90 considers r and q similar, and r ∼ q (r is a substructure of q), a similarity
score (as defined in equation 4.2.1) is calculated.
Clearly, a candidate molecule may match more than one scaffold structure, some
of which as substructures and others as superstructures, resulting in several similarity
scores computed for each candidate compound.
As previously mentioned, molecules within a typical pathway tend to have similar
structures since they are related to each other through stepwise chemical transfor-
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Figure 6.2.1: Schematic of TrackSM’s predictive process.
mations. Our hypothesis is that for a query compound cq , the larger the number of
compounds that are structurally similar to cq within a given metabolic pathway the
more likely that cq is to participate in that pathway. Also, if at least one of those scaffolds matches cq as a substructure and another as a superstructure, then that might
be more evidence of cq belonging to that pathway. TrackSM identifies the biological
function of a molecular compound in two steps. It first predicts a metabolic class
to which the molecule is likely to belong to, based on information from structurally
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similar scaffolds. Then it uses the predicted metabolic class with scaffold similarity information to predict an individual pathway to which the molecule is likely to
interact in. Figure 6.2.1 shows a general overview of the TrackSM prediction process.
I propose an algorithm to predict the biological function of a small compound by
associating it with a metabolic class and an individual metabolic pathway based on
its molecular structure alone. First we will start by defining some notations followed
by an explanation of the computational model behind TrackSM.
Let cq be the molecular structure of a query compound, S = {s1 , s2 , . . . , sn be a
set of n small compounds (scaffolds), M = {M1 , M2 , . . . , Ml } be a set of metabolic
pathway classes, and P = {p1 , p2 , . . . , pm be the set of individual pathways. Let
sx → My indicate that the scaffold sx belongs to the metabolic pathway class My
and let sx → Pz indicate that sx belongs to the individual metabolic pathway Pz
Let CL (cq ) represent the list of candidate pathway classes to which cq is predicted to
be associated with. Similarly, let P L (cq ) represent the list of candidate individual
pathways to which cq is predicted to be associated with.

6.2.1

Pathway Classes Prediction Method

TrackSM predicts the biological function of query compound cq in two steps. First,
it predicts the metabolic pathway class that cq belongs to. This step is carried out in
the following manner: cq is matched against all the scaffolds in S. If a scaffold sx is
found to be a substructure of cq , then sx is added to set S b . If a scaffold sy is found
to be a superstructure of cq , then sy is added to set Sp . Hence, let S̄ denote the set
of scaffolds that structurally match cq such that S̄ = Sb ∪ Sp . The list of candidate
metabolic classes CL (cq ) is assembled such that it represents all the metabolic classes
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associated with all the scaffolds inS̄ . For each candidate pathway class M 0 , associated
with at least one compound in S̄, a vector V (cq , M 0 ) = [Ss, Sc, Co] is populated.
Vector V (cq , M 0 ) represents the confidence that class M 0 is is the pathway class to
which cq belongs to. Let Ss be a binary value representing the existence of at least
one substructure compound and at least one superstructure compound that belong
to M 0 , i.e.

Ss =




1,




if ∃sx ∈ Sb & sy ∈ Sp ; sx → M 0 , sy → M 0





 0,

otherwise

Let Sc represent the highest SimScore (defined by equation 1) found between cq and
all the matching compounds in S̄ that belong to M’ ; Sc = maxsj S,sj →M 0 SimScore(cq , sj ).
Finally, Co is defined as the number of scaffolds in S̄ that belong to pathway class
M’ ; Co = count(sj ∈ S̄, sj M 0 ). Finally, all pathway classes in CL (cq ) are ranked as
discussed in Section 3 and the class with the highest scores is predicted to be PC, the
class to which cq is associated.

6.2.2

Individual Pathways Prediction Method

In the second step, TrackSM predicts one or more individual pathways to which
the query compound might belong to. List P L (cq ) is populated and ranked via a
method very similar to that used to populate CL (cq ) with the exception of referencing
individual pathways instead of pathway classes. Similarly, for each candidate individual pathway Pr , associated with at least one compound in S̄, a vector V (cq , Pr ) =
[Ss, Sc, Co] is populated. Vector V (cq , Pr ) represents the confidence that pathway
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Pr is the predicted pathway to which cq belongs to. Ss is a binary value representing
the existence of at least one substructure compound and at least one superstructure
compound that belong to Pr , i.e.

Ss =




1,




if ∃sx ∈ Sb & sy ∈ Sp ; sx → Pr , sy → Pr





 0,

otherwise

Let Sc represent the highest SimScore (defined by equation 1) found between cq and
all the matching compounds in S̄ that belong to Pr ; Sc = maxsj S,sj →Pr SimScore(cq , sj ).
Finally, Co is defined as the number of scaffolds in S̄that belong to pathway class Pr ;
Co = count(sj ∈ S̄sj Pr ).
Specific to predicting individual pathways, we have developed an additional method
referred to as Match90ClassBased. In this method, TrackSM uses the predicted pathway class PC in the first step to further guide its search for individual pathway associations for cq . Hence, P L (cq ) is only populated with individual pathways that have
associations with scaffolds that structurally match cq and belong to the predicted
pathway class PC. Hence, any scaffold in S̄ must belong to the predicted class PC.
All the calculations following this step are similar to that of the previously explained
method.

6.3

Dataset

Pathway information concerning 3,190 small molecules of the dataset used by Gao
et al [107], as well as their molecular structures, were downloaded (January 2013)
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from the KEGG database. The distribution of those compounds among the pathway
classes and the number of individual pathways associated with each class are shown in
Table 6.3.1. It was observed that some compounds are associated with more than one
pathway class. Others are associated with more than one individual pathway within
the same class. These observations are obvious in Table 6.3.1 since the total number
of compounds belonging to all classes is 4,404, greater than the actual number of
compounds (3,190). Figure 6.4.1a shows that 90% of the 3,190 scaffolds used in this
study are associated with only one pathway class, while 7% are associated with two
classes, and only 3% are associated with 3 or more pathway classes. Figure 6.4.1b
demonstrates the distribution of scaffolds based on their association to individual
pathways.
Of the 3,190 scaffolds, 85% are associated with one individual pathway. This
means that 5% of the compounds associated with one pathway class belong to more
than one individual pathway within that given class. Nine percent are associated
with 2 individual pathways and only 6% are associated with 3 or more individual
pathways. The mass distribution of the molecules in the scaffolds list used in this
work is displayed in Figure 6.4.1c. This figure shows that the majority of the molecules
(76%) fall in the mass range 116 – 460 Daltons.

6.4
6.4.1

Results and Discussion
Ranking Method Formulation and Selection

I formalized six possible ways for ranking the candidate classes in CL (cq ) and candidate pathways in P L (cq ) referred to as: SsScCo, ScSsCo, ScCoSs, CoScSs, CoSsSc,
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Pathway Class Name

1
2
3
4
5
6
7
8
9
10
11

Carbohydrate metabolism
Energy metabolism
Lipid metabolism
Nucleotide metabolism
Amino acid metabolism
Metabolism of other amino acids
Glycan biosynthesis and metabolism
Metabolism of cofactors and vitamins
Metabolism of terpenoids and
polyketides
Biosynthesis of other secondary
metabolites
Xenobiotics biodegradation and
metabolism
Total

Pathway
Class
Code

Number
of Compounds

CM
EM
LM
NM
ACM
MOAA
GBM
MCV
MTP

Number
of Individual
Pathways
15
7
16
2
13
9
5
12
18

BOSM

20

555

XBM

20

796

137

4404

575
193
444
137
580
170
48
365
541

Table 6.3.1: Distribution of 3,190 KEGG compounds among the 11 KEGG metabolic
pathway classes.

and SsCoSc. SsScCo indicates sorting the candidate pathway classes in CL (cq ) by
the Ss value (in descending order) then breaking ties with the pathway with the highest Sc followed by the highestCo. Table 6.4.1 shows the sensitivity acquired when
a set of LOOCV experiments predicting metabolic pathway classes were carried out
using the dataset of 3,190 KEGG compounds. It is clear that the result from SsScCo,
ScCoSs, and ScSsCo are comparable and are much better than those obtained by
SsCoSc, CoSsSc, and CoScSs. I carried out an ANOVA to check for statistical significance between the top 3 ranking methods. ANOVA results indicated no statistical
significance (P >0.05). However, SsScCo accuracy was consistently higher than the
other methods and thus was selected as the ranking method for TrackSM.
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(a)

(b)

(c)

Figure 6.4.1: Distribution of 3,190 scaffolds based on (a) the number of classes they
belong to and (b) the number of individual pathways they belong to. Panel (c) shows
the mass distribution of 3,190 scaffolds into 8 mass bins ranging from 0 922 Daltons.
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Classes
Predicted
1
2
3

Ranking
SsScCo
84.92%
92.82%
95.39%

Method
ScCoSs
84.73%
92.76%
95.27%

ScSsCo
83.76%
92.23%
95.14%

SsCoSc
64.70%
81.38%
89.78%

CoSsS C
50.47%
73.17%
86.36%

CoScSs
50.41%
73.13%
86.36%

Table 6.4.1: SENS of each ranking method when TrackSM predicts 1, 2 or 3 classes
per candidate compound.

6.4.2

Performance of the Predictive Method for Metabolic
Pathway Classes

Here, I evaluated the predictive method by a set of LOOCV experiments using a
dataset of 3,190 KEGG compounds. The 1st and 2nd order of predictions made by
Gao et al(Gao et al. 2012) as well as those of TrackSM using both Match100 and
Match90 with the SsScCo ranking method are shown in Figure 6.4.2. TrackSM was
able to predict at least one correct pathway class for 85% of the compounds using
Match90 versus 79% when using Match100. Both methods reflect an improvement
over the results reported by Gao et al (77% [107]).
Actually, TrackSM using Match90 predicted only one class per query compound
had a 4% improvement in SENS over Gao et al.’s method when they predicted 2
classes per compound. This also indicates that TrackSM has a better PPV than that
of Gao et al. When TrackSM using Match90 made two class predictions per candidate
compound, 93% of the 3,190 compounds had at least one correct class prediction.
Additionally, I’ve distributed the 3,190 compounds into 8 bin masses. Results from
both prediction method (Match100 and Match90 ) were compared in each bin. Figure
6.4.3a displays the 1st order of class predictions made by TrackSM using Match100
versus Match90. It indicates that Match90 outperforms Match100 across all the bins.
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Figure 6.4.2: LOOCV prediction accuracy of the 1st and 2nd orders of predictions
made by Gao et al’s method, TrackSM with Match100, and TrackSM with Match90
when predicting metabolic pathway classes.
Figure 6.4.3b plots the SENS in each bin when Match90 was applied. The plot shows
that TrackSM is capable of predicting the metabolic class of a given compound in
the mass range 231 – 460 Da with 93% accuracy. It also shows that bins 3 through 7
acquire an average SENS of 90%. While the average SENS at bin 1 and bin 8 is 70%.
We think that predictions at both ends of the mass range are poorer because as the
compounds get very large or very small, there is a higher chance for them to match
with many scaffolds as substructures only or superstructures only, respectively. As
that happens, many noise matches are introduced causing the decrease in sensitivity.
Figure 6.4.4 shows the distribution of the 1st order of Match90 class predictions
based on a compound’s molecular mass and the number of pathway classes it is
associated with. The first bar in each subsection shows the overall predictions per
number of class associations. Match90 can predict at least one class to which a
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(a)

(b)

Figure 6.4.3: Breakdown of the 1st order of Class predictions made by Match100
versus those made by Match90 for 3,190 compounds based on molecular mass from a
set of LOOCV experiments.
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compound might belong to with a SENS of 85%, 80%, 83%, and 85% for compounds
associated with one, two, three, and four or more classes, respectively. This hints
that the number of class associations that a compound has does not really affect
the prediction quality of TrackSM. It is clear from figure 5 that the predictions for
compounds that belong to more than one metabolic class do not follow the same
distribution (based on mass) as that of those associated to only on class. There is a
good chance that this is the case because only 10% of the compounds used in this
analysis are associated with more than one class. So there does not exist enough
representation of those compounds to make such a claim.

Figure 6.4.4: Accuracy of mass bins per number of class associations for TrackSM
when using Match90 to predict metabolic pathway classes.
To further analyze our results, we assembled the results to explore the prediction
distribution based on class associations. Figure 6.4.5 shows the distribution of compounds among the 11 KEGG metabolic classes based on the 1st order of prediction
produced by Match100 versus Match90. In this analysis, only 2,874 of the com-
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pounds were included as they are associated with only one class. Match100 had a 4%
improvement over Match90 when associating compounds to class EM. Both methods performed equivalently when associating compounds to classes CM, MOAA, and
XBM. Match90 outperformed Match100 in the other 7 classes with a highest improvement of 18% in class MTP.
Also, Match90 is capable of correctly associating 90% of the compounds belonging
to six metabolic classes specifically BOSM, CM, LM, MTP, NM, and XBM. It was also
noted that Match90 could only correctly associate 44% of the compounds belonging
to class EM. Likely, this is due to the small size of class EM, with only 45 scaffold
associations.

Figure 6.4.5: Distribution of class predictions when using Match100 versus Match90
based on the query compound’s class association.
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6.4.3

Performance of the predictive method for individual
Metabolic Pathways

In this section I investigate using TrackSM to predict individual pathways to which
a candidate compound might belong to. I show results from applying Match100,
Match90 as well as a method exclusive to pathway predictions referred to as Match90ClassBased.
Figure 6.4.6 shows the SENS of the 1st , 2nd , and 3rd orders of prediction when using
Match100, Match90, and Match90ClassBased. Match90ClassBased outperformed the
other two methods. Specifically, with the 1st order of individual pathway prediction,
Match90ClassBased had 80% accuracy, while Match100 had only 66% and Match90
had a 69%. When making 2 predictions per query compound, Match90ClassBased
was able to predict at least one individual pathway for 88% of the compounds.

Figure 6.4.6: Prediction accuracy of the 1st, 2nd and 3rd orders of predictions made
by TrackSM with Match100, Match90 and Match90ClassBased when predicting individual metabolic pathways.
Finally, we’ve distributed the 3,190 compounds into 8 bin masses. Results from
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each prediction method (Match100 and Match90ClassBased ) were compared in each
bin. Figure 6.4.7a displays the 1st order of individual pathway predictions made by
TrackSM using Match100 versus Match90ClassBased. It is obvious that Match90ClassBased
outperforms Match100 across all the bins except bin 1 (0 – 115 Da). Figure 6.4.7b
plots the SENS in each bin when Match90ClassBased was applied to predict one individual pathway per query compound. The plot shows that TrackSM is capable of
predicting the metabolic class of a given compound in the mass range 346 – 460 Da
and 691 – 805 Da with 94% accuracy. It also elaborates that bins 4 through 7 acquire
an average SENS of 92%. Similar to pathway class predictions, individual pathway
predictions for compounds on both ends of the mass spectrum are of noticeably lower
sensitivity than the rest of the bins.

6.5

Conclusions

In this chapter, I presented TrackSM; a bioinformatics tool designed to predict the
metabolic pathway classes as well as the individual pathways to which small molecules
might be associated with, based only on their molecular structures. TrackSM can
place molecules in the context of metabolic pathways since it can link potentially unknown biochemicals to matched substructure and superstructure scaffolds for which
metabolic pathways are known. Validation experiments show that TrackSM is capable of associating 93% of the structures to their correct pathway classes as defined by
KEGG and 88% of them to the correct individual KEGG pathway. These impressive results suggest that TrackSM may be a valuable tool to aid in recognizing the
biochemical functions of small molecules.
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(a)

(b)

Figure 6.4.7: Percentage of compounds with at least one correct individual pathway
prediction when compounds are distributed by mass amongst 8 mass bins.

Chapter 7
Conclusions and Recommendations

7.1

Conclusions

Although there has been a long-standing interest in metabolic profiling, only recently
have technologies emerged that enable the global analysis of metabolites at a systems
level, comparable to its omic predecessors. Unlike genomics, transcriptomics and
proteomics, however, metabolomics provides a tool for measuring biochemical activity directly by monitoring the substrates and products transformed during cellular
metabolism. Untargeted profiling of these chemical transformations at a global level
serves as a phenotypic readout that can be used effectively in diagnosing pathologies, identifying therapeutic targets of disease and investigating the mechanisms of
fundamental biological processes.
In this thesis, I described the development and validation of BioSM, a novel supervised classifier that uses endogenous mammalian biochemical scaffolds to predict
whether a candidate chemical structure is biochemical or synthetic. BioSM was able
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to correctly classify 96% of 3,750 biochemical compounds in a leave-one-out cross validation experiment. In addition, our results suggest that approximately 13% of PubChem compounds are mammalian biochemicals. Next, I introduced BioSMXpress, a
tool designed to enhance the performance of BioSM. I showed that BioSMXpress is,
on an average, 8 times faster than BioSM without compromising the quality of the
predictions made. BioSMXpress will be an extremely useful tool in the timely identification of unknown biochemical structures in metabolomics. BioSMXpress may be
specifically useful for searching large chemical databases in metabolomics applications
where the number of potential false positives is very large. BioSMXpress can be easily
tailored to specific application domains. For example, if one is interested in identifying unknown chemical structures in plant samples, the current scaffolds list can be
supplemented with known plant biochemical structures and the NBS list could be
appropriately modified Finally, I presented TrackSM; a bioinformatics tool designed
to predict the metabolic pathway classes as well as the individual pathways to which
small molecules might be associated with, based only on their molecular structures.
TrackSM can place molecules in the context of metabolic pathways since it can link
potentially unknown biochemicals to matched substructure and superstructure scaffolds for which metabolic pathways are known. Validation experiments show that
TrackSM is capable of associating 93% of the structures to their correct pathway
classes as defined by KEGG and 88% of them to the correct individual KEGG pathway. These impressive results suggest that TrackSM may be a valuable tool to aid in
recognizing the biochemical functions of small molecules.
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7.2

Recommendations for future work

Based on the work presented in this thesis, I presnt the following recommendations
for future work:
∗ Include compounds with halogens. Currently, BioSMXpress does not allow
annotation of candidate compounds with halogens (ie, F, Cl, Br) since the
current scaffolds list is based upon endogenous human biochemical compounds.
∗ Metabolomics pipeline. Currently BioSMXpress and TrackSM are two independent programs. I would like to create a pipleline such that the inputs/outputs of
BioSMXpress would be automatically handed to TrackSM. Results from both
programs would be presented together.
∗ User-friendly website. I would like to develop a user-friendly web-based application where users can input one or more molecular structure(s) and get a
prediction whether the structure(s) looks biochemical or not in addition to the
pathway class and individual pathway it might interact with.
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